Combination therapy of interleukin-2 (il-2) analog or conjugate thereof and immune checkpoint inhibitor for preventing or treating cancer

MYPI2025004879A0Undetermined Publication Date: 2024-09-07HANMI PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025004879
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-07
Filing Date
2024-03-07
Publication Date
2024-09-07

AI Technical Summary

Technical Problem

Current cancer treatments using interleukin 2 are limited by severe toxicities and side effects, such as vascular leak syndrome, and immune checkpoint inhibitors face challenges with immune evasion by cancer cells, necessitating a safer and more effective combination therapy.

Method used

A combination therapy using a novel interleukin 2 analog or long-acting conjugate with increased binding affinity to the interleukin 2 beta receptor, administered in conjunction with an immune checkpoint inhibitor, to enhance anti-tumor effects while minimizing side effects.

Benefits of technology

The combination therapy effectively inhibits tumor growth, improves survival rates, and induces memory responses, providing a safer and more effective cancer treatment by activating the immune system against cancer cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025004879_DRAWING_001
    Figure PI2025004879_DRAWING_001
  • Figure PI2025004879_DRAWING_002
    Figure PI2025004879_DRAWING_002
  • Figure PI2025004879_DRAWING_003
    Figure PI2025004879_DRAWING_003
Patent Text Reader

Abstract

The present invention relates to a combined use of an interleukin-2 analog or conjugate thereof and an immune checkpoint inhibitor for preventing or treating cancer and a pharmaceutical composition comprising the same.
Need to check novelty before this filing date? Find Prior Art

Description

Combination therapy of interleukin 2 analogues or their conjugates and immune checkpoint inhibitors for the prevention or treatment of cancer

[0001] The present invention relates to a combination therapy of an interleukin 2 analog or a combination thereof and an immune checkpoint inhibitor for the prevention or treatment of cancer.

[0002] Interleukin-2 (IL-2) is an important immunostimulant composed of 133 amino acid residues and a molecular weight of approximately 15 kDa. It activates various cells of the immune system, including T cells and B cells. The high efficacy of IL-2 as an immunostimulant can be used to treat various immune-related diseases, including cancer and AIDS (Korean Patent Publication No. 10-2017-0070091). Currently, IL-2 (trade name: Proleukin) is an FDA-approved drug for the treatment of metastatic renal cell carcinoma and metastatic melanoma. However, the serious toxicities associated with high-dose IL-2 therapy limit the number of eligible patients, and only a small number of eligible patients receive this treatment. Toxicity associated with IL-2 includes high fever, nausea, vomiting, vascular leak, severe hypotension, pulmonary edema, and vascular leak syndrome, which causes liver damage.

[0003]

[0004] The interleukin 2 receptor (IL-2R) has three subunit receptors. These subunits are composed of an alpha chain (IL-2Rα, CD25), a beta chain (IL-2Rβ or CD122), and a gamma chain (IL-2Rγ or CD132). IL-2 can exert various functions by binding to various combinations of receptor subunits. The single interleukin 2 alpha receptor is called the low-affinity interleukin 2 receptor and is not involved in signal transduction. The complex of interleukin 2 beta and gamma receptors binds to interleukin 2 with intermediate affinity. The complex of interleukin 2 alpha, beta, and gamma receptors binds to interleukin 2 with high affinity. The complex of interleukin 2 beta and gamma receptors is necessary for efficient signal transduction through kinase activation of multiple signaling pathways. The interleukin 2 beta and gamma receptors are particularly prominent on CD8+ cells and natural killer (NK) cells. Additionally, complexes of high-affinity interleukin 2 alpha, beta, and gamma receptors are usually CD4 + It is found in recently activated T cells as well as T regulatory cells (Treg). Interleukin 2 beta receptor is CD8 + Since it is distributed in T cells or natural killer cells (NK cells) and participates in the body's immune response, research is being conducted to develop a treatment by increasing the activity of beta receptors to activate the immune system.

[0005]

[0006] Meanwhile, immune cells typically possess proteins called immune checkpoints on their cell membranes. These proteins suppress unnecessary autoimmune responses and detect tumor-specific antigens expressed by cancer cells due to mutations and other changes, thereby eliminating cancer cells. However, cancer cells alter the function of these immune checkpoints to evade these immune responses, suppressing T cell function and preventing an appropriate immune response.

[0007]

[0008] Immune checkpoint inhibitors are treatments that activate the patient's autoimmune system, inducing the body's immune cells to suppress cancer cell growth. Unlike existing immunotherapies, they bind to the binding site between cancer cells and T cells, blocking immune evasion signals. This allows T cells to destroy cancer cells without being affected by immune evasion. Therefore, research is ongoing to use immune checkpoint inhibitors in immunotherapy for cancer patients.

[0009]

[0010] Treatment methods that activate the human immune system in this way and allow the body's immune cells to act on cancer cells to achieve an anticancer effect are being actively researched. However, when drugs that stimulate the immune system are used in cancer treatment, side effects due to immune cell overactivation are problematic, so it is necessary to discover safe and effective anticancer treatments and therapies.

[0011]

[0012] There is a need to develop safe therapeutic agents and treatment regimens using these agents that can activate the immune system and exhibit anticancer effects.

[0013]

[0014] One object of the present invention is to provide a pharmaceutical composition for preventing or treating cancer, comprising an interleukin 2 analog or a long-acting conjugate thereof, characterized in that the pharmaceutical composition is administered in combination with an immune checkpoint inhibitor.

[0015] Another object of the present invention is to provide a therapy for preventing or treating cancer using an interleukin 2 analog or a long-acting conjugate thereof and an immune checkpoint inhibitor.

[0016] Another object of the present invention is to provide a combination comprising an interleukin 2 analog or a long-acting conjugate thereof; and an immune checkpoint inhibitor.

[0017] Another object of the present invention is to provide a pharmaceutical composition for preventing, improving or treating cancer, comprising the above combination.

[0018] Another object of the present invention is to provide a pharmaceutical kit for preventing, improving or treating cancer, comprising an interleukin 2 analog or a long-acting conjugate thereof; and an immune checkpoint inhibitor.

[0019] Another object of the present invention is to provide a method for preventing or treating cancer, comprising administering and / or using the combination, pharmaceutical composition, or pharmaceutical kit to a subject in need thereof.

[0020] Another object of the present invention is to provide a method for preventing, improving or treating cancer, comprising the step of co-administering and / or co-using a composition containing a pharmaceutically effective amount of an interleukin 2 analog or a long-acting conjugate thereof and a composition containing a pharmaceutically effective amount of an immune checkpoint inhibitor to a subject in need thereof.

[0021] Another object of the present invention is to provide a use of the combination, pharmaceutical composition, or pharmaceutical kit for preventing, improving, or treating cancer; and / or for the manufacture of a medicament for preventing, improving, or treating cancer.

[0022]

[0023] A pharmaceutical composition for preventing or treating cancer comprising an interleukin 2 analog or a long-acting conjugate thereof according to the present invention can be used as an excellent anticancer treatment agent by exhibiting a tumor growth inhibitory effect while reducing side effects when administered in combination with an immune checkpoint inhibitor.

[0024]

[0025] Figure 1 shows the SDS-PAGE results of interleukin 2 analog long-acting conjugates (analogs 21, 41, and 52).

[0026] Figures 2a to 2c show the purity analysis results of interleukin 2 analog long-acting conjugates (analogs 21, 41, and 52).

[0027] Figure 3 shows the results of evaluating the antitumor efficacy of combination therapy of an interleukin 2 analog long-acting conjugate and an immune checkpoint inhibitor (anti-PD-1 antibody) in a malignant melanoma animal model, in which aldesleukin or interleukin 2 analog 86 conjugate was administered alone, or aldesleukin and interleukin 2 analog 86 conjugate were administered in combination with an immune checkpoint inhibitor, respectively, and the tumor size (A in Figure 3) and the survival rate (B in Figure 3) of the mouse model were confirmed. The dosage of the long-acting conjugate in Figure 3 is a value expressed only based on the weight occupied by the interleukin 2 analog portion in the entire conjugate.

[0028] Figure 4 shows the results of evaluating the antitumor efficacy of combination therapy with an interleukin-2 analog long-acting conjugate and an immune checkpoint inhibitor (anti-PD-1 antibody) in a lung cancer animal model, and the results of confirming the tumor size in a mouse model in which aldesleukin or interleukin-2 analog 86 conjugate was administered alone, or aldesleukin and interleukin-2 analog 86 conjugate were administered in combination with an immune checkpoint inhibitor, respectively. In Figure 4, the dosage of the long-acting conjugate is a value expressed only based on the weight occupied by the interleukin-2 analog portion of the entire conjugate.

[0029] Figure 5 shows the results of an analysis of the antitumor efficacy of combination therapy of an interleukin-2 analog long-acting conjugate and an immune checkpoint inhibitor (anti-PD-1 antibody) in a lung cancer animal model using the Bliss independent model. In Figure 5, the dosage of the long-acting conjugate is expressed only based on the weight of the interleukin-2 analog portion of the entire conjugate.

[0030] Figure 6 shows the results of a combination therapy of a long-acting interleukin-2 analog conjugate and an immune checkpoint inhibitor (anti-PD-1 antibody) in a pancreatic cancer mouse model, demonstrating anticancer efficacy and relapse prevention efficacy through memory responses. The dosage of the long-acting conjugate in Figure 6 is based solely on the weight of the interleukin-2 analog portion of the entire conjugate.

[0031]

[0032] One aspect of the present invention is a composition comprising a novel interleukin 2 analog (or IL-2 analog) or a long-acting conjugate thereof, characterized in that the composition is administered in combination with an immune checkpoint inhibitor. The interleukin 2 (IL-2) analog is an interleukin 2 analog having increased interleukin 2 beta receptor binding affinity compared to natural interleukin 2 or aldesleukin, which is an interleukin 2 analog, and may include a sequence in which one or more amino acids are mutated in natural interleukin 2.

[0033] As a specific example, the interleukin 2 analog is characterized by comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3 to 106.

[0034] As another specific example, the persistent conjugate is characterized by being a persistent conjugate represented by the following chemical formula 1:

[0035] [Chemical Formula 1]

[0036] X - L - F

[0037] At this time, X is an interleukin 2 analog comprising any one sequence selected from the amino acid sequences of SEQ ID NOs: 3 to 106;

[0038] L is a polyethylene glycol linker;

[0039] F is the immunoglobulin Fc region in dimeric form;

[0040] - indicates a covalent bond between X and L, and between L and F,

[0041] The above-mentioned persistent complex is covalently linked to one end of L only in one polypeptide chain of the Fc region of the dimer form, and covalently linked to X in the opposite end of L.

[0042] A composition according to any one of the preceding specific examples, wherein the sustained-release conjugate comprises, as a part of the conjugate, an interleukin 2 analog having altered interleukin 2 alpha receptor binding affinity and enhanced interleukin 2 beta receptor binding affinity compared to native interleukin 2 or aldesleukin.

[0043] A composition according to any one of the preceding specific examples, wherein the interleukin 2 analog is characterized by increased binding affinity for the interleukin 2 beta receptor compared to aldesleukin.

[0044] A composition according to any one of the preceding specific examples, wherein the interleukin 2 analog is selected from the group consisting of SEQ ID NOs: 10, 13 to 15, 17, 20 to 22, 32, 35, 36, 42, 53, 54, 56, 58 to 60, 62, 71, 72, 74 to 78, 85, 87, 89, 91 to 94, and 97 to 106 10, 13, 14, 16, 17, 20, 21, 22, 32, 35, 36, 42, 53, 54, 87, 89, 91, 92, 93, 94, 98, 99, 100, 101, 103, 104, and It is characterized by comprising any one sequence selected from the group consisting of 105 amino acid sequences.

[0045] A composition according to any one of the preceding specific examples, wherein the interleukin 2 analog comprises any one sequence selected from the group consisting of amino acid sequences of SEQ ID NOs: 17, 22, 42, 53, 56, 58 to 60, 62, 71, 72, 74 to 77, 87, 89, 91 to 93, 98 to 101, and 103 to 106.

[0046] A composition according to any one of the preceding specific examples, wherein the interleukin 2 analog comprises any one sequence selected from the group consisting of amino acid sequences of SEQ ID NOs: 22, 42, 53, 87, 105 and 106.

[0047] A composition according to any one of the preceding specific examples, wherein the interleukin 2 analogue further comprises one or more amino acids at the C-terminus.

[0048] A composition according to any one of the preceding specific examples, wherein the immune checkpoint inhibitor is a PD-1 antagonist.

[0049] A composition according to any one of the preceding specific examples, wherein the immune checkpoint inhibitor is at least one selected from an anti-PD-1 antibody or an antigen-binding fragment thereof.

[0050] A composition according to any one of the preceding specific examples, wherein the anti-PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, cemiplimab, spartalizumab, camrelizumab, sintilimab, tislelizumab, toripalimab, dostarlimab, INCMGA00012, AMP-224 and AMP-514.

[0051] A composition according to any one of the preceding specific examples, characterized in that the sustained binding agent comprises an IgG4 Fc region.

[0052] A composition according to any one of the preceding specific examples, wherein the sustained binding agent comprises an aglycosylated immunoglobulin Fc region.

[0053] A composition according to any one of the preceding specific examples, wherein the immunoglobulin Fc region is derived from a non-glycosylated Fc region derived from human IgG4.

[0054] A composition according to any one of the preceding specific examples, wherein the immunoglobulin Fc region has a structure in which two polypeptide chains are linked by a disulfide bond, and is characterized in that the two chains are linked only through a nitrogen atom of one of the two chains.

[0055] A composition according to any one of the preceding specific examples, wherein the immunoglobulin Fc region comprises a monomer having an amino acid sequence of SEQ ID NO: 438.

[0056] A composition according to any one of the preceding specific examples, wherein the immunoglobulin Fc region is a homodimer of monomers having an amino acid sequence of SEQ ID NO: 438.

[0057] A composition according to any one of the preceding specific examples, wherein the immunoglobulin Fc region is linked via a nitrogen atom of its N-terminal proline.

[0058] A composition according to any one of the preceding specific examples, wherein the sustained binding agent is characterized in that X is covalently linked to one of the Fc regions of the dimeric immunoglobulin Fc regions via the polyethylene glycol linker.

[0059] A composition according to any one of the preceding specific examples, characterized in that one end of the linker is linked to only one Fc region chain of the two Fc region chains of the dimeric form immunoglobulin Fc region.

[0060] A composition according to any one of the preceding specific examples, wherein the polyethylene glycol linker is a linker having a molecular weight of 1 kDa to 100 kDa.

[0061] A composition according to any one of the preceding specific examples, characterized in that the composition further comprises a pharmaceutically acceptable excipient.

[0062] A composition according to any one of the preceding specific examples, wherein the cancer is renal cell carcinoma, melanoma, colon cancer, liver cancer, uterine cancer, ovarian cancer, pancreatic cancer, gallbladder cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, skin cancer, breast cancer, bladder cancer, stomach cancer, head or neck cancer, esophageal cancer, laryngeal cancer, bone cancer, rectal cancer, anal cancer, colon cancer, fallopian tube carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, small intestine cancer, endocrine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, renal pelvic carcinoma, CNS tumor, primary CNS lymphoma, spinal cord tumor, brain tumor, glioma (astrocytoma, glioblastoma), It is characterized by being any one selected from the group consisting of oligodendroglioma, ependymoma, germ cell tumor, meningioma, brainstem glioma, pituitary adenoma, schwannoma, congenital tumor, craniopharyngioma, and brain tumor.

[0063] A composition according to any one of the preceding specific examples, wherein the cancer is a cancer type having low responsiveness to a PD-1 antagonist.

[0064] A composition according to any one of the preceding specific examples, wherein the cancer having low responsiveness to the PD-1 antagonist is characterized as being an immune-impermeable tumor (cold tumor).

[0065] A composition according to any one of the preceding specific examples, wherein the composition is characterized in that it is administered by an intraperitoneal, intravenous, intramuscular, subcutaneous, intradermal, oral, topical, intranasal, intrapulmonary, or rectal route.

[0066] A composition according to any one of the preceding specific examples, characterized in that the composition is administered at time intervals ranging from one week to one month.

[0067] A composition according to any one of the preceding specific examples, characterized in that the composition is administered concurrently, sequentially or in reverse order with an immune checkpoint inhibitor or a composition comprising the same.

[0068] Another aspect of the present invention is a method for preventing or treating cancer, comprising administering to a subject the interleukin 2 analog or a long-acting conjugate thereof, or a composition comprising the same, and an immune checkpoint inhibitor or a composition comprising the same.

[0069] Another aspect of the present invention is a combined use of the interleukin 2 analog or a long-acting conjugate thereof, or a composition comprising the same, and an immune checkpoint inhibitor or a composition comprising the same for the prevention or treatment of cancer.

[0070] Another aspect of the present invention is a use for providing a drug for preventing or treating cancer, comprising the interleukin 2 analog or a long-acting conjugate thereof, or a composition comprising the same, when administered in combination with an immune checkpoint inhibitor.

[0071] Another aspect of the present invention is a pharmaceutical kit comprising the interleukin 2 analog or a long-acting conjugate thereof, or a pharmaceutical kit for co-administering the interleukin 2 analog or a long-acting conjugate thereof with an immune checkpoint inhibitor.

[0072]

[0073] The specific details for implementing the present invention are as follows. Meanwhile, each description and embodiment disclosed in this application can also be applied to each other description and embodiment. That is, all combinations of the various elements disclosed in this application fall within the scope of the present invention. Furthermore, the scope of the present invention is not limited by the specific descriptions described below. Furthermore, numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated into this specification in their entirety by reference to more clearly explain the level of the technical field to which the present invention pertains and the contents of the present invention.

[0074]

[0075] Throughout this specification, conventional one-letter and three-letter codes for amino acids are used. Amino acids referred to by abbreviations herein are described according to the IUPAC-IUB nomenclature.

[0076] Alanine A Arginine R

[0077] Asparagine N Aspartic acid D

[0078] Cysteine ​​C Glutamic Acid E

[0079] Glutamine Q Glycine G

[0080] Histidine H Isoleucine I

[0081] Leucine L Lysine K

[0082] Methionine M Phenylalanine F

[0083] Proline P Serine S

[0084] Threonine T Tryptophan W

[0085] Tyrosine Y Valine V

[0086]

[0087]

[0088] One aspect of the present invention provides a pharmaceutical composition for preventing or treating cancer, comprising an interleukin 2 analog or a long-acting conjugate thereof, which composition is administered in combination with an immune checkpoint inhibitor.

[0089] The interleukin 2 analog of the present invention is characterized by having altered binding affinity for the interleukin 2 receptor, particularly by having enhanced binding affinity for the interleukin 2 beta receptor. Specifically, the interleukin 2 analog of the present invention may have enhanced binding affinity for the interleukin 2 beta receptor compared to native interleukin 2 or known aldesleukin, and more specifically, may have altered (increased or decreased) binding affinity for the interleukin 2 alpha receptor, and may include a sequence in which one or more amino acids are mutated in native interleukin 2.

[0090]

[0091] One embodiment of the composition of the present invention may include, but is not limited to, an interleukin 2 analog comprising, consisting essentially of, or consisting of any one sequence selected from the amino acid sequences of SEQ ID NOs: 3 to 106.

[0092]

[0093] Specifically, the composition of the present invention may be a pharmaceutical composition for preventing or treating cancer comprising an interleukin 2 analog or a long-acting conjugate thereof, and more specifically, may be a pharmaceutical composition for preventing or treating cancer comprising an interleukin 2 analog or a long-acting conjugate thereof and a pharmaceutically acceptable excipient, and administered in combination with an immune checkpoint inhibitor, but is not limited thereto.

[0094]

[0095] The pharmaceutical composition of the present invention

[0096] a) administered as a mixture comprising (i) an interleukin-2 analog or a long-acting conjugate thereof; and (ii) an immune checkpoint inhibitor; or

[0097] b) (i) an interleukin 2 analog or a long-acting conjugate thereof; and (ii) an immune checkpoint inhibitor may be administered in a separate form, but is not limited thereto.

[0098] For example, the interleukin 2 analog or its long-acting conjugate; and the immune checkpoint inhibitor may be formulated as a single formulation, or may be formulated separately. If the interleukin 2 analog or its long-acting conjugate; and the immune checkpoint inhibitor are in separate forms, the interleukin 2 analog or its long-acting conjugate; and the immune checkpoint inhibitor may be formulated as separate formulations that can be administered simultaneously, separately, sequentially, or in reverse order.

[0099] In the present invention, combination administration should be understood not only to mean simultaneous administration, but also to mean a dosage form in which an interleukin-2 analog or a long-acting conjugate thereof; and an immune checkpoint inhibitor act together in a subject so that each substance can perform its original function at a level equal to or greater than that of the original substance. Therefore, the term "combination" herein should be understood to include simultaneous, separate, sequential, or reverse administration of an interleukin-2 analog or a long-acting conjugate thereof; and an immune checkpoint inhibitor. When the administration is sequential, reverse, or separate, the order of administration is not particularly limited, but the interval between administrations of the second component should be such that the beneficial effect of the combination is not lost.

[0100]

[0101] The interleukin 2 analog or its long-acting conjugate, and the immune checkpoint inhibitor of the present invention; or a composition comprising them, may be provided in the form of a kit, but is not limited thereto. The term “kit” in the present invention may include a composition according to the present invention for co-administration of an interleukin 2 analog or its long-acting conjugate and an immune checkpoint inhibitor. Specifically, the kit according to the present invention may include an interleukin 2 analog or its long-acting conjugate, and an immune checkpoint inhibitor formulated as a single formulation, or may include separate formulations of an interleukin 2 analog or its long-acting conjugate, and an immune checkpoint inhibitor, and may additionally include a substance necessary for co-administration of the two substances, but is not limited thereto.

[0102]

[0103] In the present invention, the term "interleukin 2 (IL-2)" refers to an immune modulator, a type of cytokine that transmits signals in the immune system in vivo. Interleukin 2 is generally known as an important immune stimulant of approximately 15 kDa.

[0104] In the present invention, the term "interleukin 2 analog" means one or more amino acids mutated from the native sequence, and in particular, in the present invention, it may be an interleukin 2 analog in which an amino acid of the native interleukin 2 is mutated, such that the binding affinity for the interleukin 2 receptor is reduced or increased compared to the native interleukin 2. Specifically, the interleukin 2 analog of the present invention may be non-naturally occurring.

[0105] The above natural interleukin 2 may be human interleukin 2, and its sequence may be obtained from a known database, etc. Specifically, it may be the amino acid sequence of sequence number 1, but is not limited thereto.

[0106] In the present invention, the meaning that the natural interleukin 2 can be the amino acid sequence of SEQ ID NO: 1 means that not only the sequence identical to SEQ ID NO: 1, but also the sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homology with SEQ ID NO: 1 belongs to the category of the natural interleukin 2 of the present invention, and the position of the amino acid mutation means that when the sequences having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homology with SEQ ID NO: 1 are aligned, the corresponding position on the amino acid sequence of SEQ ID NO: 1 is mutated.

[0107]

[0108] In the present invention, the term “aldesleukin” refers to a commercially available interleukin 2 analog, which may be aldesleukin (trade name: Proleukin®), and specifically, may have an amino acid sequence of SEQ ID NO: 2. In the present invention, it is used interchangeably with “interleukin 2 analog 1.” The interleukin 2 analog according to the present invention may have an altered interleukin 2 alpha receptor binding affinity and / or an increased interleukin 2 beta receptor binding affinity compared to the interleukin 2 analog 1.

[0109] Although the interleukin 2 alpha receptor is not known to be involved in the signaling pathway of interleukin 2, it increases the binding affinity of interleukin 2 to other interleukin 2 receptors (beta or gamma) by 10- to 100-fold, and CD4 + It is expressed in regulatory T cells, etc.

[0110] Interleukin 2 beta receptor is CD8 +It is mainly distributed in T cells or natural killer cells (NK cells) and performs a major function in activating immune responses and macrophage function, so tumor cell death and activation of the body's immune response can be expected through activation of the interleukin 2 beta receptor.

[0111] Therefore, the interleukin 2 analog of the present invention with increased binding affinity to the interleukin 2 beta receptor can have a therapeutic effect with increased therapeutic effects such as tumor suppression and apoptosis, and reduced side effects.

[0112]

[0113] As an example, the interleukin 2 analog may comprise, consist essentially of, or consist of, but is not limited to, an amino acid sequence selected from the group consisting of SEQ ID NOs: 3 to 106.

[0114] In one specific embodiment, the interleukin 2 analog consists of an amino acid sequence of SEQ ID NOs: 10, 13 to 15, 17, 20 to 22, 32, 35, 36, 42, 53, 54, 56, 58 to 60, 62, 71, 72, 74 to 78, 85, 87, 89, 91 to 94, and 97 to 106 10, 13, 14, 16, 17, 20, 21, 22, 32, 35, 36, 42, 53, 54, 87, 89, 91, 92, 93, 94, 98, 99, 100, 101, 103, 104, and 105. It may comprise, consist essentially of, or consist of, but is not limited to, any one sequence selected from the group.

[0115] In another specific embodiment, the interleukin 2 analog may comprise, consist essentially of, or consist of any one sequence selected from the group consisting of amino acid sequences of SEQ ID NOs: 17, 22, 42, 53, 56, 58 to 60, 62, 71, 72, 74 to 77, 87, 89, 91 to 93, 98 to 101, and 103 to 106, but is not limited thereto. In another specific embodiment, the interleukin 2 analog may comprise, consist essentially of, or consist of any one sequence selected from the group consisting of amino acid sequences of SEQ ID NOs: 10, 13, 14, 15, 16, 17, 20, 21, 22, 32, 35, 36, 42, 53, 54, 56, 58, 59, 60, 62, 71, 72, 74, 75, It may comprise, consist essentially of, or consist of any one sequence selected from the group consisting of amino acid sequences of 76, 77, 78, 85, 87, 89, 91, 92, 93, 94, 95, 98, 99, 100, 101, 103, 104, 105, and 106, but is not limited thereto.

[0116] In another specific embodiment, the interleukin 2 analog may comprise, consist essentially of, or consist of any one sequence selected from the group consisting of amino acid sequences of SEQ ID NOs: 10, 13, 14, 16, 17, 20, 21, 22, 32, 35, 36, 42, 53, 54, 87, 89, 91, 92, 93, 94, 98, 99, 100, 101, 103, 104, and 105, but is not limited thereto.

[0117] In another specific embodiment, the interleukin 2 analog may comprise, consist essentially of, or consist of any one sequence selected from the group consisting of amino acid sequences of SEQ ID NOs: 22, 42, 53, 87, 105, and 106, but is not limited thereto.

[0118] Additionally, the interleukin 2 analog may additionally include one or more amino acids at the C-terminus, but is not limited thereto.

[0119]

[0120] In addition, even if it is described in this specification as 'an interleukin 2 analog composed of a specific sequence number', if it has the same or corresponding activity as an interleukin 2 analog composed of an amino acid sequence of the sequence number, it does not exclude meaningless sequence additions before and after the amino acid sequence of the sequence number, mutations that may occur naturally, or silent mutations thereof, and it is clear that even if it has such sequence additions or mutations, it falls within the scope of the present invention.

[0121] The interleukin 2 analog of the present invention may include an amino acid sequence having 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more homology or identity to the amino acid sequence of SEQ ID NOs: 3 to 106, but is not limited thereto.

[0122] In the present invention, the term 'homology' or 'identity' means the degree to which two given amino acid sequences or base sequences are related to each other, and may be expressed as a percentage.

[0123] Sequence homology or identity of conserved polynucleotides or polypeptides is determined by standard alignment algorithms, and may be combined with default gap penalties established by the program being used. In practice, homologous or identical sequences can generally hybridize with all or part of the sequence under moderate or high stringency conditions. It should be appreciated that hybridization also includes hybridization with polynucleotides containing common codons or codons that take codon degeneracy into account.

[0124] The terms homology and identity are often used interchangeably.

[0125] Whether any two base sequences or peptide sequences are homologous, similar, or identical can be determined using a known computer algorithm, such as the "FASTA" program with default parameters, for example, as in Pearson et al (1988) [Proc. Natl. Acad. Sci. USA 85]: 2444. Alternatively, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) (version 5.0.0 or later) can be used. (including the GCG program package (Devereux, J., et al, Nucleic Acids Research 12: 387 (1984)), BLASTP, BLASTN, FASTA (Atschul, [S.] [F.,] [ET AL, J MOLEC BIOL 215]: 403 (1990); Guide to Huge Computers, Martin J. Bishop, [ED.,] Academic Press, San Diego,1994, and [CARILLO ETA / .](1988) SIAM J Applied Math 48: 1073). For example, BLAST from the National Center for Biotechnology Information database, or ClustalW can be used to determine homology, similarity, or identity.

[0126] Homology, similarity, or identity of nucleotide sequences or peptides can be determined by comparing sequence information using a GAP computer program, e.g., as disclosed in Smith and Waterman, Adv. Appl. Math (1981) 2:482, or, e.g., as disclosed in Needleman et al. (1970), J Mol Biol. 48: 443. In brief, the GAP program defines the GAP as the total number of symbols in the shorter of the two sequences divided by the number of similarly arranged symbols (i.e., nucleotides or amino acids). Default parameters for the GAP program include (1) a unary comparison matrix (containing values ​​of 1 for identity and 0 for non-identity) and (2) a univariate comparison matrix, as disclosed in Schwartz and Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation, pp. 353-358 (1979), as disclosed in Gribskov et al. (1986) Nucl. Acids Res. 48: 443. 14: 6745 weighted comparison matrix (or EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix); (2) a penalty of 3.0 for each gap and an additional penalty of 0.10 for each symbol in each gap (or a gap opening penalty of 10 and a gap extension penalty of 0.5); and (3) no penalty for terminal gaps. Therefore, as used herein, the term "homology" or "identity" refers to the relevance between sequences.

[0127]

[0128] The interleukin 2 analog of the present invention can be used as a novel alternative to interleukin 2 that changes in vitro activity by weakening or increasing binding affinity for interleukin 2 alpha and / or beta receptors. In particular, it can be used as an effective therapeutic agent due to its activity against both receptors by not only increasing binding affinity for beta receptors but also changing (increasing or decreasing) binding affinity for alpha receptors.

[0129]

[0130] In the present invention, such modifications for the production of an analog of interleukin 2 include modifications using L- or D-type amino acids, and / or non-natural amino acids; and / or modifications of the native sequence, for example, modifications of side chain functional groups, intramolecular covalent bonds, such as ring formation between side chains, methylation, acylation, ubiquitination, phosphorylation, aminohexaoxidation, biotinylation, etc.

[0131] Additionally, it includes all of those in which one or more amino acids are added to the amino and / or carboxy terminus of native interleukin 2.

[0132] The amino acids substituted or added above can include the 20 amino acids commonly found in human proteins, as well as atypical or non-naturally occurring amino acids. Commercial sources of atypical amino acids include Sigma-Aldrich, ChemPep, and Genzyme pharmaceuticals. Peptides containing these amino acids and their typical peptide sequences can be synthesized and purchased from commercial peptide synthesis companies, such as American Peptide Company or Bachem in the United States, or Anygen in Korea.

[0133] Amino acid derivatives can also be obtained in a similar manner, examples of which include 4-imidazoacetic acid.

[0134]

[0135] In addition, the interleukin 2 analog according to the present invention may be in a modified form in which the N-terminus and / or C-terminus thereof are chemically modified or protected with an organic group, or an amino acid is added to the peptide terminus, etc., in order to protect against protein cleavage enzymes in the body and increase stability.

[0136] In particular, in the case of chemically synthesized peptides, since the N- and C-terminals are charged, the N-terminus may be acetylated and / or the C-terminus amidated to remove the charge, but is not particularly limited thereto.

[0137]

[0138] The interleukin 2 analog of the present invention can be synthesized through a solid phase synthesis method, can be produced by a recombinant method, and can be manufactured commercially, but is not limited thereto.

[0139] Additionally, the interleukin 2 analog of the present invention can be synthesized by a method well known in the art, for example, by an automatic peptide synthesizer, depending on its length, and can also be produced by genetic engineering technology.

[0140] Specifically, the interleukin 2 analog of the present invention can be prepared by standard synthetic methods, recombinant expression systems, or any other method known in the art. Accordingly, the interleukin 2 analog of the present invention can be synthesized by a number of methods, including, for example, methods including:

[0141] (a) a method of synthesizing a peptide stepwise or by fragment assembly by means of a solid-phase or liquid-phase method, and isolating and purifying the final peptide product; or

[0142] (b) a method of expressing a nucleic acid construct encoding a peptide in a host cell and recovering the expression product from the host cell culture; or

[0143] (c) a method for performing cell-free in vitro expression of a nucleic acid construct encoding a peptide and recovering the expression product; or

[0144] A method for obtaining fragments of a peptide by any combination of (a), (b) and (c), then linking the fragments to obtain a peptide, and recovering the peptide.

[0145]

[0146] In the present invention, the binding affinity of any interleukin 2 analog (or a long-lasting binder including the same) to a natural interleukin 2 receptor can be measured using surface plasmon resonance (SPR) as a method for measuring the affinity for the receptor.

[0147] Specifically, during SPR analysis, the interleukin 2 receptor is immobilized on a sensor chip using the protein-ligand binding principle, and an interleukin 2 analog diluted in an experimental buffer is flowed using a serial dilution method to induce binding to the immobilized receptor, and then only the experimental buffer is flowed at the same flow rate to induce dissociation of the receptor and the interleukin 2 analog to measure the binding strength, or an antibody against the human immunoglobulin Fc region is first immobilized on the sensor chip, and then the interleukin 2 receptor bound to the Fc region is immobilized and the interleukin 2 analog is flowed to measure the binding strength, but the present invention is not limited thereto.

[0148] More specifically, a biotin-labeled human interleukin 2 receptor is immobilized on a streptavidin biosensor chip, and an interleukin 2 analog long-acting conjugate diluted in HBS-EP+ buffer is flowed at a flow rate of 20 μL per minute for 3 minutes using a two-fold serial dilution method, and then only HBS-EP+ buffer is flowed at the same flow rate for 3 minutes to induce dissociation of the interleukin 2 receptor and the interleukin 2 analog long-acting conjugate, and then the obtained binding constant and dissociation constant can be used to measure the binding strength according to a 1:1 binding fitting model using a Bioaevaluation program, but is not limited thereto.

[0149] More specifically, the interleukin 2 analog of the present invention may have reduced or increased interleukin 2 alpha receptor binding affinity compared to native interleukin 2 or aldesleukin (or interleukin 2 analog 1).

[0150] Specifically, the interleukin 2 analog of the present invention may have an interleukin 2 alpha receptor binding affinity of about 0.001 times or more, about 0.005 times or more, about 0.01 times or more, about 0.05 times or more, about 0.1 times or more, about 0.3 times or more, about 0.5 times or more, about 0.7 times or more, about 0.9 times or more, about 1.1 times or more, about 1.3 times or more, about 1.5 times or more, or about 1.7 times or more compared to the interleukin 2 alpha receptor binding affinity of natural interleukin 2 or aldesleukin, but the numerical value is not limited, and if the binding affinity is changed compared to natural interleukin 2 or aldesleukin, it falls within the scope of the present invention.

[0151] Alternatively, based on the interleukin 2 alpha receptor binding affinity (100%) of aldesleukin, the interleukin 2 analog of the present invention may have lost the binding affinity at all, or may have a binding affinity of about 1% or more, about 5% or more, about 7% or more, about 10% or more, about 15% or more, about 20% or more, about 30% or more, about 50% or more, about 70% or more, about 90% or more, about 100% or more, about 150% or more, or about 200% or more, but the numerical value is not limited, and if the binding affinity is changed compared to natural interleukin 2 or aldesleukin, it falls within the scope of the present invention.

[0152]

[0153] In addition, specifically, the interleukin 2 analog of the present invention may have an interleukin 2 beta receptor binding affinity of about 0.1 times or more, about 0.3 times or more, about 0.5 times or more, about 0.7 times or more, about 1.0 times or more, about 10 times or more, about 20 times or more, about 30 times or more, about 40 times or more, about 50 times or more, about 60 times or more, about 70 times or more, about 80 times or more, about 90 times or more, or about 100 times or more compared to the interleukin 2 beta receptor binding affinity of natural interleukin 2 or aldesleukin, but the numerical value is not limited, and if the binding affinity is changed or increased compared to natural interleukin 2 or aldesleukin, it falls within the scope of the present invention.

[0154] Alternatively, based on the interleukin 2 beta receptor binding affinity (100%) of aldesleukin, the interleukin 2 analog of the present invention may have a binding affinity of about 5% or more, about 9% or more, about 10% or more, about 20% or more, about 30% or more, about 50% or more, about 100% or more, about 200% or more, about 500% or more, about 700% or more, about 1000% or more, about 1500% or more, about 3000% or more, about 5000% or more, about 7000% or more, about 10000% or more, about 12000% or more, about 15000% or more, about 20000% or more, or about 25000% or more, but the numerical value is not limited, and if the binding affinity is increased compared to natural interleukin 2 or aldesleukin, it falls within the scope of the present invention.

[0155]

[0156] In the present invention, the term "about" includes all ranges including ±0.5, ±0.4, ±0.3, ±0.2, ±0.1, etc., and includes all numerical values ​​in a range equal to or similar to the numerical value following the term "about," but is not limited thereto.

[0157] The interleukin 2 analog of the present invention is characterized by having altered binding affinity for the interleukin 2 alpha receptor and increased binding affinity for the interleukin 2 beta receptor compared to natural interleukin 2 or aldesleukin.

[0158]

[0159] In a specific embodiment of the present invention, in order to manufacture the interleukin 2 analog of the present invention, an interleukin 2 analog was manufactured by introducing a mutation based on the natural interleukin 2 (SEQ ID NO: 1). The interleukin 2 analog manufactured in the present invention may include any one of the amino acid sequences of SEQ ID NOs: 3 to 106, or may be encoded by any one of the base sequences of SEQ ID NOs: 108 to 211.

[0160]

[0161] The nucleic acid encoding the interleukin 2 analog of the present invention may be modified to introduce a mutation (amino acid deletion, substitution, and / or addition) to an amino acid at a specific position in the base sequence encoding the native interleukin 2 of SEQ ID NO: 1, and specifically may include a base sequence encoding any one of the amino acid sequences of SEQ ID NOs: 3 to 106. As an example, the nucleic acid of the present invention may have or include any one of the base sequences of SEQ ID NOs: 108 to 211.

[0162] The base sequence of the present invention can be modified in various ways in the coding region within a range that does not change the amino acid sequence of the interleukin 2 analog of the present invention, taking into account the degeneracy of the codon or the codon preferred in the organism that is to express the nucleic acid of the present invention. Specifically, the nucleic acid of the present invention may have or include a base sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and less than 100% homology or identity with any one of the sequences of SEQ ID NOs: 108 to 211, or may consist of or consist essentially of a base sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and less than 100% homology or identity with any one of the sequences of SEQ ID NOs: 108 to 211, but is not limited thereto.

[0163] In addition, the nucleic acid of the present invention may include, without limitation, a probe that can be prepared from a known genetic sequence, for example, a sequence that can hybridize under stringent conditions with a complementary sequence to all or part of the nucleic acid sequence of the present invention. The "stringent conditions" above refer to conditions that enable specific hybridization between polynucleotides. Such conditions are specifically described in the literature (see J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press, Cold Spring Harbor, New York, 1989; F. M. Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York, 9.50-9.51, 11.7-11.8).

[0164] Hybridization requires that two nucleic acids have complementary sequences, although mismatches between bases are possible depending on the stringency of hybridization. The term "complementary" is used to describe the relationship between nucleotide bases that can hybridize with each other. For example, in DNA, adenine is complementary to thymine, and cytosine is complementary to guanine. Therefore, the nucleic acids of the present invention may also include isolated nucleic acid fragments that are complementary in their entirety, as well as nucleic acid sequences that are substantially similar.

[0165] The appropriate stringency for hybridizing the polynucleotides depends on the length and degree of complementarity of the polynucleotides, variables which are well known in the art (e.g., J. Sambrook et al., supra).

[0166] As for homology or identity, it is as described above.

[0167]

[0168] Additionally, the interleukin 2 analog of the present invention may have an increased half-life in the body compared to natural interleukin or aldesleukin, but is not particularly limited thereto. For example, a biocompatible material for increasing half-life (e.g., an immunoglobulin Fc region) may be bound directly or via a linker to the interleukin 2 analog to form a sustained-release conjugate with an increased half-life, but is not limited thereto.

[0169] The sustained-release conjugate according to the present invention not only includes an interleukin 2 analog with enhanced binding affinity to the interleukin 2 beta receptor, but also binds to an immunoglobulin Fc region as a representative carrier for increasing the half-life thereof, thereby increasing the half-life of the interleukin 2 analog, increasing its exposure in the blood, and increasing the immune response in the body, thereby effectively achieving the inhibition and reduction of cancer cell growth.

[0170]

[0171] The above may be applied to other specific examples or other aspects of the present invention, but is not limited thereto.

[0172]

[0173] Another embodiment of the composition of the present invention may include, but is not limited to, a sustained-release conjugate of the interleukin 2 analog.

[0174]

[0175] In the present invention, the interleukin 2 analog sustained-release conjugate may be in the form of a biocompatible material conjugated to the interleukin 2 analog to increase its in vivo half-life. In the present specification, the biocompatible material may be mixed with a carrier.

[0176] In the present invention, the sustained-release conjugate can exhibit increased duration of efficacy compared to an interleukin 2 analogue not bound to a carrier, and in the present invention, such a conjugate is referred to as a “sustained-release conjugate” or “conjugate.”

[0177] On the other hand, these combinations may be non-naturally occurring.

[0178]

[0179] In one specific example of the present invention, the persistent conjugate is a persistent conjugate represented by the following chemical formula 1:

[0180] [Chemical Formula 1]

[0181] X - L - F

[0182] Here, X is the interleukin 2 analog;

[0183] L is a polyethylene glycol linker;

[0184] F is the immunoglobulin Fc region in dimeric form;

[0185] - indicates a covalent bond between X and L, and between L and F,

[0186] The above-mentioned persistent complex is covalently linked to one end of L only in one polypeptide chain of the Fc region of the dimer form, and covalently linked to X in the opposite end of L.

[0187] More specifically, the sustained conjugate may be one in which one molecule of X is linked to one polypeptide chain in the Fc region via L. In addition, in the sustained conjugate of the present invention, X and L, and L and F may be linked to each other via a covalent bond, and in this case, the conjugate may be a conjugate in which X, L, and F are linked to each other via a covalent bond in the order of Chemical Formula 1.

[0188]

[0189] The interleukin 2 analog of the sustained-release complex of the present invention is characterized by having altered binding affinity for the interleukin 2 receptor, particularly enhanced binding affinity for the interleukin 2 beta receptor, when it exists alone without forming a part of the complex. Specifically, the interleukin 2 analog of the present invention may have enhanced binding affinity for the interleukin 2 beta receptor compared to native interleukin 2 or known aldesleukin when it exists alone without forming a part of the complex, and more specifically, may also have altered (increased or decreased) binding affinity for the interleukin 2 alpha receptor.

[0190]

[0191] In the present invention, the interleukin 2 analog may correspond to the composition of one moiety constituting the conjugate. Specifically, it corresponds to X in the above chemical formula 1, and the interleukin 2 analog is as described above.

[0192] In the above complex, F is a substance capable of increasing the half-life of X, i.e., an interleukin 2 analog, and corresponds to one component of a moiety constituting the complex of the present invention.

[0193] The above F may be bonded to X through a covalent chemical bond, and F and X may be bonded to each other through L through a covalent chemical bond.

[0194] Specifically, the F is an immunoglobulin Fc region, and the immunoglobulin Fc region may be an IgG Fc region or an aglycosylated IgG4 Fc region, but is not particularly limited thereto.

[0195] As a specific example of the present invention, the F (immunoglobulin Fc region) is a dimer composed of two polypeptide chains, and may have a structure in which one terminal of L is connected to only one of the two polypeptide chains, but is not limited thereto.

[0196]

[0197] One or more amino acid side chains within the peptides of the present invention may be conjugated to such biocompatible substances to increase their solubility and / or half-life in vivo and / or to increase their bioavailability. Such modifications may also reduce the clearance of the therapeutic proteins and peptides.

[0198] The biocompatible material described above may be water-soluble (amphiphilic or hydrophilic) and / or non-toxic and / or pharmaceutically acceptable.

[0199]

[0200] In one specific embodiment, the sustained binding agent of the present invention may be, but is not limited to, an interleukin 2 analog and an immunoglobulin Fc region linked thereto.

[0201]

[0202] In the present invention, the "immunoglobulin Fc region" refers to a region including the heavy chain constant region 2 (CH2) and / or the heavy chain constant region 3 (CH3) portion, excluding the heavy and light chain variable regions of an immunoglobulin. The immunoglobulin Fc region may be a component forming a moiety of the complex of the present invention. Specifically, it corresponds to F in the above chemical formula 1.

[0203] As used herein, the term "Fc region" encompasses not only the native sequence obtained by papain digestion of immunoglobulin, but also derivatives thereof, such as variants such as sequences in which one or more amino acid residues in the native sequence are altered by deletion, insertion, non-conservative or conservative substitution, or a combination thereof, so as to be different from the native sequence. The derivatives, substituted products, and variants are assumed to have the ability to bind to FcRn. In the present invention, F may be a human immunoglobulin region, but is not limited thereto. As used herein, "biocompatible material" or "carrier" may refer to the Fc region.

[0204] The above F (immunoglobulin Fc region) has a structure in which two polypeptide chains are connected by a disulfide bond, and may be a structure in which only the nitrogen atom of one of the two chains is connected, but is not limited thereto. The connection via the nitrogen atom may be connected through reductive amination to the epsilon amino atom of lysine or the N-terminal amino group.

[0205] A reductive amination reaction is a reaction in which an amine group or amino group of a reactant reacts with an aldehyde of another reactant (i.e., a functional group capable of reductive amination) to produce an amine, and then an amine bond is formed through a reduction reaction. It is an organic synthesis reaction widely known in the relevant technical field.

[0206] As one specific example of the sustained-release conjugate of the present invention, the sustained-release conjugate may be one in which the immunoglobulin Fc region is linked to a linker via its N-terminal nitrogen atom.

[0207]

[0208] Such immunoglobulin Fc regions may include, but are not limited to, a hinge region in the heavy chain constant region.

[0209] In the present invention, the immunoglobulin Fc region may include a specific hinge sequence at the N-terminus.

[0210] The term "hinge sequence" of the present invention refers to a region located in the heavy chain that forms a dimer of the immunoglobulin Fc region through an inter disulfide bond.

[0211] In the present invention, the hinge sequence may be mutated to have only one cysteine ​​residue by deleting a portion of the hinge sequence having the following amino acid sequence, but is not limited thereto:

[0212] Glu-Ser-Lys-Tyr-Gly-Pro-Pro-Cys-Pro-Ser-Cys-Pro (SEQ ID NO: 418).

[0213] The above hinge sequence may be one in which the 8th or 11th cysteine ​​residue of the hinge sequence of SEQ ID NO: 418 is deleted, thereby containing only one cysteine ​​residue. The hinge sequence of the present invention may be composed of 3 to 12 amino acids, including only one cysteine ​​residue, but is not limited thereto. More specifically, the hinge sequence of the present invention may have the following sequences: Glu-Ser-Lys-Tyr-Gly-Pro-Pro-Pro-Ser-Cys-Pro (SEQ ID NO: 419), Glu-Ser-Lys-Tyr-Gly-Pro-Pro-Cys-Pro-Ser-Pro (SEQ ID NO: 420), Glu-Ser-Lys-Tyr-Gly-Pro-Pro-Cys-Pro-Ser (SEQ ID NO: 421), Glu-Ser-Lys-Tyr-Gly-Pro-Pro-Cys-Pro-Pro (SEQ ID NO: 422), Lys-Tyr-Gly-Pro-Pro-Cys-Pro-Ser (SEQ ID NO: 423), Glu-Ser-Lys-Tyr-Gly-Pro-Pro-Cys (SEQ ID NO: 424), Glu-Lys-Tyr-Gly-Pro-Pro-Cys (SEQ ID NO: 425), Glu-Ser-Pro-Ser-Cys-Pro (SEQ ID NO: 426), Glu-Pro-Ser-Cys-Pro (SEQ ID NO: 427), Pro-Ser-Cys-Pro (SEQ ID NO: 428), Glu-Ser-Lys-Tyr-Gly-Pro-Pro-Ser-Cys-Pro (SEQ ID NO: 429), Lys-Tyr-Gly-Pro-Pro-Ser-Cys-Pro (SEQ ID NO: 430), Glu-Ser-Lys-Tyr-Gly-Pro-Ser-Cys-Pro (SEQ ID NO: 431), Glu-Ser-Lys-Tyr-Gly-Pro-Pro-Cys (SEQ ID NO: 432), Lys-Tyr-Gly-Pro-Pro-Cys-Pro (SEQ ID NO: 433), Glu-Ser-Lys-Pro-Ser-Cys-Pro (SEQ ID NO: 434), Glu-Ser-Pro-Ser-Cys-Pro (SEQ ID NO: 435), Glu-Pro-Ser-Cys (SEQ ID NO: 436), Ser-Cys-Pro (SEQ ID NO: 437).

[0214] More specifically, the hinge sequence may include, but is not limited to, the amino acid sequence of SEQ ID NO: 428 (Pro-Ser-Cys-Pro) or SEQ ID NO: 437 (Ser-Cys-Pro).

[0215] In a more specific form of the sustained-release conjugate of the present invention, the N-terminus of the immunoglobulin Fc region in the conjugate is proline, and the conjugate is one in which the Fc region is linked to a linker via the nitrogen atom of the proline.

[0216] In one embodiment of the sustained-release conjugate of the present invention, the immunoglobulin Fc region may be in the form of a dimer in which two chains of the immunoglobulin Fc region form a homodimer or a heterodimer due to the presence of a hinge sequence. The conjugate of chemical formula 1 of the present invention may be in the form in which one end of the linker is connected to one chain of the immunoglobulin Fc region of the dimer, but is not limited thereto.

[0217] The term "N-terminus" of the present invention refers to the amino terminus of a protein or polypeptide, and may include the most amino acid, or 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more amino acids from the most amino acid. The immunoglobulin Fc region of the present invention may include a hinge sequence at the N-terminus, but is not limited thereto.

[0218]

[0219] In addition, the immunoglobulin Fc region of the present invention may be an extended Fc region including part or all of the heavy chain constant region 1 (CH1) and / or the light chain constant region 1 (CL1) of an immunoglobulin, excluding only the heavy and light chain variable regions, as long as it has substantially the same or improved effects as the native type. It may also be a region in which a relatively long portion of the amino acid sequence corresponding to CH2 and / or CH3 is removed.

[0220] For example, the immunoglobulin Fc region of the present invention may be, but is not limited to, 1) a CH1 domain, a CH2 domain, a CH3 domain, and a CH4 domain, 2) a CH1 domain and a CH2 domain, 3) a CH1 domain and a CH3 domain, 4) a CH2 domain and a CH3 domain, 5) a combination of one or more domains from among the CH1 domain, the CH2 domain, the CH3 domain, and the CH4 domain with an immunoglobulin hinge region (or a portion of the hinge region), or 6) a dimer of each domain of a heavy chain constant region and a light chain constant region.

[0221] In the present invention, the immunoglobulin Fc region may be in the form of a dimer or multimer composed of single-chain immunoglobulins composed of domains of the same origin, but is not limited thereto.

[0222]

[0223] In addition, as one embodiment of the sustained-release complex of the present invention, the immunoglobulin Fc region F is a dimer composed of two polypeptide chains, wherein the Fc region dimer F and X are covalently linked via a linker L containing an ethylene glycol repeating unit. In one specific example of this embodiment, X is covalently linked via the linker L to only one of the two polypeptide chains of the Fc region dimer F. In a more specific example of this embodiment, only one molecule of X is covalently linked via L to one of the two polypeptide chains of the Fc region dimer F to which X is linked. In the most specific example of this embodiment, the F is a homodimer.

[0224] In another specific embodiment, the immunoglobulin Fc region F may be a dimer composed of two polypeptide chains, and one terminus of L may be linked to only one of the two polypeptide chains, but is not limited thereto.

[0225] In another embodiment of the sustained binding agent of the present invention, it is also possible for two molecules of X to symmetrically bind to one Fc region in a dimeric form. In this case, the immunoglobulin Fc region and X may be linked to each other by L. However, the present invention is not limited to the examples described above.

[0226] In addition, the immunoglobulin Fc region of the present invention includes not only a native amino acid sequence but also a sequence derivative thereof. An amino acid sequence derivative means a sequence having a different sequence due to deletion, insertion, non-conservative or conservative substitution, or a combination thereof, of one or more amino acid residues in the native amino acid sequence.

[0227] For example, in the case of IgG Fc, amino acid residues 214 to 238, 297 to 299, 318 to 322 or 327 to 331, which are known to be important for binding, can be used as suitable sites for modification.

[0228] In addition, various types of derivatives are possible, such as those in which the site capable of forming disulfide bonds is removed, several amino acids at the N-terminus of the native Fc are removed, or a methionine residue is added to the N-terminus of the native Fc. In addition, complement binding sites, such as the C1q binding site, or the ADCC (antibody dependent cell mediated cytotoxicity) site may be removed to eliminate effector function. Techniques for producing such sequence derivatives of the immunoglobulin Fc region are disclosed in International Patent Publication Nos. WO 97 / 34631 and WO 96 / 32478, among others.

[0229] Amino acid exchanges in proteins and peptides that do not alter the overall activity of the molecule are well known in the art (H.Neurath, RLHill, The Proteins, Academic Press, New York, 1979). The most common exchanges are between amino acid residues Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Thy / Phe, Ala / Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu, Asp / Gly. In some cases, modifications such as phosphorylation, sulfation, acrylation, glycosylation, methylation, farnesylation, acetylation, and amidation may also occur.

[0230] The Fc derivative described above exhibits biological activity equivalent to the Fc region of the present invention and may have increased structural stability of the Fc region against heat, pH, etc.

[0231] In addition, such Fc region may be obtained from a natural type isolated from an animal such as a human, cow, goat, pig, mouse, rabbit, hamster, rat or guinea pig, or may be a recombinant or a derivative thereof obtained from a transformed animal cell or microorganism. Here, the method for obtaining from a natural type may be a method of isolating the entire immunoglobulin from a human or animal body and then treating it with a protease to obtain it. When treated with papain, it is cleaved into Fab and Fc, and when treated with pepsin, it is cleaved into pF'c and F(ab)2. Fc or pF'c can be separated using size-exclusion chromatography or the like. In a more specific embodiment, the Fc region of human origin is a recombinant immunoglobulin Fc region obtained from a microorganism.

[0232] In addition, the immunoglobulin Fc region may have native sugar chains, sugar chains with increased sugar chains compared to the native form, sugar chains with decreased sugar chains compared to the native form, or sugar chains removed. Conventional methods such as chemical methods, enzymatic methods, and genetic engineering methods using microorganisms can be used to increase or remove the sugar chains of the immunoglobulin Fc. Here, the immunoglobulin Fc region from which the sugar chains have been removed has a significantly reduced binding affinity to complement (c1q), and antibody-dependent cytotoxicity or complement-dependent cytotoxicity is reduced or eliminated, so it does not induce unnecessary immune responses in vivo. In this respect, the form that is more suitable for the original purpose as a drug carrier is an immunoglobulin Fc region from which the sugar chains have been removed or deglycosylated.

[0233] In the present invention, “deglycosylation” refers to an Fc region from which sugars have been removed by an enzyme, and aglycosylation refers to an Fc region that has not been glycosylated and produced in a prokaryotic animal, or in a more specific embodiment, in E. coli.

[0234] Meanwhile, the immunoglobulin Fc region may be of animal origin such as human or cow, goat, pig, mouse, rabbit, hamster, rat, guinea pig, etc., and in a more specific embodiment, is of human origin.

[0235] Additionally, the immunoglobulin Fc region may be an Fc region derived from IgG, IgA, IgD, IgE, IgM, or a combination thereof or a hybrid thereof. In a more specific embodiment, it is derived from IgG or IgM, which is most abundant in human blood, and in an even more specific embodiment, it is derived from IgG, which is known to enhance the half-life of a ligand binding protein. In a still more specific embodiment, the immunoglobulin Fc region is an IgG4 Fc region, and in a most specific embodiment, the immunoglobulin Fc region is a non-glycosylated Fc region derived from human IgG4, but is not limited thereto.

[0236] Also, as a specific example, the immunoglobulin Fc region may be a fragment of human IgG4 Fc, which may be a homodimer in which two monomers are linked via a disulfide bond (inter-chain form) between cysteines at amino acid positions 35 and 95 of each monomer, and wherein the homodimer has / may have two disulfide bonds (intra-chain form) between cysteines at positions 35 and 95 and between cysteines at positions 141 and 199 of each monomer.

[0237] Each monomer may be composed of 221 amino acids, and the amino acids forming the homodimer may be composed of a total of 442 amino acids, but is not limited thereto. Specifically, the immunoglobulin Fc fragment forms a homodimer by forming a disulfide bond between two monomers having the amino acid sequence of SEQ ID NO: 438 (composed of 221 amino acids) between cysteine ​​amino acids at position 3 of each monomer, and the monomers of the homodimer may independently form an internal disulfide bond between cysteines at positions 35 and 95 and an internal disulfide bond between cysteines at positions 141 and 199, but are not limited thereto.

[0238] F in the above chemical formula 1 may include a monomer having an amino acid sequence of SEQ ID NO: 438, and F may be a homodimer of a monomer having an amino acid sequence of SEQ ID NO: 438, but is not limited thereto.

[0239] As an example, the immunoglobulin Fc region may be a homodimer comprising, but is not limited to, the amino acid sequence of SEQ ID NO: 439 (consisting of 442 amino acids).

[0240] In one specific example, the immunoglobulin Fc region and X may be non-glycosylated, but are not limited thereto.

[0241]

[0242] Meanwhile, in the present invention, "combination" means that when forming a dimer or multimer, a polypeptide encoding a single-chain immunoglobulin Fc region of the same origin forms a bond with a single-chain polypeptide of different origin. That is, it is possible to produce a dimer or multimer from two or more fragments selected from the group consisting of Fc fragments of IgG Fc, IgA Fc, IgM Fc, IgD Fc, and IgE.

[0243] In the present invention, the term "hybrid" means that a sequence corresponding to two or more different origin immunoglobulin Fc fragments exists within a single-chain immunoglobulin constant region. In the present invention, various types of hybrids are possible. That is, a hybrid of domains consisting of one to four domains from the group consisting of CH1, CH2, CH3, and CH4 of IgG Fc, IgM Fc, IgA Fc, IgE Fc, and IgD Fc is possible, and may include a hinge.

[0244] Meanwhile, IgG can also be divided into subclasses of IgG1, IgG2, IgG3, and IgG4, and combinations or hybridizations of these are also possible in the present invention. Specifically, the subclasses are IgG2 and IgG4, and most specifically, the Fc region of IgG4, which has almost no effector functions such as complement-dependent cytotoxicity (CDC).

[0245] In addition, the above-described conjugate may have an increased duration of effect compared to natural interleukin 2 or aldesleukin, or compared to X in which F is not modified, and such conjugate includes, but is not limited to, not only the above-described form but also a form encapsulated in biodegradable nanoparticles.

[0246]

[0247] In the present invention, the "polyethylene glycol linker" includes a biocompatible polymer having two or more ethylene glycol repeating units bonded together. The repeating units are linked to each other via any covalent bond other than a peptide bond. The polyethylene glycol linker may be a component forming a moiety of the conjugate of the present invention, and in the present specification, the linker may be used interchangeably with "non-peptide linker" or "non-peptide polymer."

[0248] In one specific embodiment, the conjugate may be one in which F and X are covalently linked to each other via a non-peptide linker comprising reactive groups capable of binding to F (specifically an immunoglobulin Fc region) and X (specifically an interleukin 2 analog) at both ends.

[0249] Specifically, in the present invention, the non-peptide linker includes a reactive group at the terminal, and can form a complex through a reaction with another component constituting the complex. When a non-peptide linker having reactive functional groups at both terminals binds to X and F of the above chemical formula 1 through each reactive group to form a complex, the non-peptide linker or non-peptide polymer can be referred to as a non-peptide polymer linker moiety or a non-peptide linker linker moiety.

[0250]

[0251] In one specific embodiment, the L (polyethylene glycol linker) may be a linker containing ethylene glycol repeating units, for example, polyethylene glycol, but is not limited thereto. As used herein, the polyethylene glycol is a term encompassing all forms of ethylene glycol homopolymers, PEG copolymers, or monomethyl-substituted PEG polymers (mPEG), but is not particularly limited thereto. In addition, derivatives thereof already known in the art and derivatives that can be easily prepared within the skill level of the art are also included in the scope of the present invention.

[0252] The above polyethylene glycol linker may include an ethylene glycol repeating unit and, before being formed into a conjugate, may include a functional group at the terminal that is used in the production of the conjugate. The sustained conjugate according to the present invention may be in a form in which X and F are linked through the functional group, but is not limited thereto. In the present invention, the non-peptide linker may include two or three or more functional groups, and each functional group may be the same or different from each other, but is not limited thereto.

[0253] Specifically, the linker may include a repeating unit represented by the following chemical formula 2. An example thereof may be, but is not limited to, polyethylene glycol (PEG):

[0254] [Chemical Formula 2]

[0255]

[0256]

[0257] Here, n= 10 to 2400, n= 10 to 480, or n= 50 to 250, but is not limited thereto.

[0258] In the above persistent conjugate, the PEG moiety is -(CH2CH2O) n -Not only the structure but also the connecting elements and this -(CH2CH2O) n - may also include, but is not limited to, intervening oxygen atoms.

[0259]

[0260] As a specific example, the ethylene glycol repeating unit may be represented by, for example, [OCH2CH2]n, and the value of n may be a natural number and may be determined such that the average molecular weight of the [OCH2CH2]n moiety in the interleukin 2 analog conjugate is, for example, a number average molecular weight of greater than 0 to about 100 kDa, but is not limited thereto. As another example, the n value is a natural number, and the average molecular weight of the [OCH2CH2]n portion in the interleukin 2 analog conjugate, for example, the number average molecular weight is about 1 to about 100 kDa, about 1 to about 80 kDa, about 1 to about 50 kDa, about 1 to about 30 kDa, about 1 to about 25 kDa, about 1 to about 20 kDa, about 1 to about 15 kDa, about 1 to about 13 kDa, about 1 to about 11 kDa, about 1 to about 10 kDa, about 1 to about 8 kDa, about 1 to about 5 kDa, about 1 to about 3.4 kDa, about 2 to about 30 kDa, about 3 to about 30 kDa, about 3 to about 27 kDa, about 3 to about 25 kDa, About 3 to about 22 kDa, about 3 to about 20 kDa, about 3 to about 18 kDa, about 3 to about 16 kDa, about 3 to about 15 kDa, about 3 to about 13 kDa, about 3 to about 11 kDa, about 3 to about 10 kDa, about 3 to about 8 kDa, about 3 to about 5 kDa, about 3 to about 3.It may be, but is not limited to, 4 kDa, about 8 to about 30 kDa, about 8 to about 27 kDa, about 8 to about 25 kDa, about 8 to about 22 kDa, about 8 to about 20 kDa, about 8 to about 18 kDa, about 8 to about 16 kDa, about 8 to about 15 kDa, about 8 to about 13 kDa, about 8 to about 11 kDa, about 8 to about 10 kDa, about 9 to about 15 kDa, about 9 to about 14 kDa, about 9 to about 13 kDa, about 9 to about 12 kDa, about 9 to about 11 kDa, about 9.5 to about 10.5 kDa, or about 10 kDa.

[0261]

[0262] Additionally, in one specific embodiment, the complex may be a structure in which an interleukin 2 analog and an immunoglobulin Fc region (F) are covalently linked via a linker (L) containing ethylene glycol repeating units, but is not limited thereto.

[0263] In another specific embodiment, in the sustained conjugate, L may be a linker containing ethylene glycol repeating units, and F may be a dimeric immunoglobulin Fc region. More specifically, one molecule of X may be covalently linked to one Fc region of the dimeric immunoglobulin Fc region via the linker containing ethylene glycol repeating units, but is not limited thereto. In addition, in another specific embodiment, one end of the linker containing ethylene glycol repeating units may be linked to only one Fc region chain of the two Fc region chains of the dimeric immunoglobulin Fc region, but is not limited thereto.

[0264] The molecular weight of the polyethylene glycol linker that can be used in the present invention may be in the range of more than 0 to 200 kDa, specifically, in the range of about 1 to 100 kDa, in the range of about 1 to 50 kDa, in the range of about 1 to 30 kDa, in the range of about 2 to 30 kDa, in the range of about 1 to 20 kDa, more specifically, in the range of about 3.4 kDa to 10 kDa, and more specifically, about 3.4 kDa, but is not limited thereto. In addition, the non-peptide linker of the present invention that is bound to the polypeptide corresponding to F may use not only one type of polymer but also a combination of different types of polymers.

[0265] In the present invention, the term "about" includes all ranges including ±0.5, ±0.4, ±0.3, ±0.2, ±0.1, etc., and includes all numerical values ​​in a range equal to or similar to the numerical value following the term "about," but is not limited thereto.

[0266]

[0267] Specifically, the non-peptide linker may have reactive groups at both ends without being bound to F and X, and may be bound to F and X through the reactive groups.

[0268] In one specific example, both ends of the linker can be bound to a thiol group, an amino group, a hydroxyl group of an immunoglobulin Fc region and a thiol group, an amino group, an azide group, a hydroxyl group of an interleukin 2 analog (X), but are not limited thereto.

[0269] Specifically, the linker may include a reactive group capable of binding to an immunoglobulin Fc region and an interleukin 2 analog (X) at both ends, specifically, a thiol group of cysteine ​​of the immunoglobulin Fc region; an amino group located at the N-terminus, lysine, arginine, glutamine and / or histidine; and / or a hydroxyl group located at the C-terminus, and may include a reactive group capable of binding to a thiol group of cysteine ​​of the interleukin 2 analog (X); an amino group of lysine, arginine, glutamine and / or histidine; an azide group of azidolysine; and / or a hydroxyl group, but is not limited thereto.

[0270] More specifically, the reactive group of the linker may be one or more selected from the group consisting of an aldehyde group, a maleimide group, and a succinimide derivative, but is not limited thereto.

[0271] In the above, examples of the aldehyde group include, but are not limited to, a propionaldehyde group or a butyraldehyde group.

[0272] In the above, succinimidyl derivatives may include, but are not limited to, succinimidyl valerate, succinimidyl methylbutanoate, succinimidyl methylpropionate, succinimidyl butanoate, succinimidyl propionate, N-hydroxysuccinimide, hydroxy succinimidyl, succinimidyl carboxymethyl, or succinimidyl carbonate.

[0273] The above linker can be converted into a linker linkage by being linked to F, an immunoglobulin Fc region, and X, an interleukin 2 analog, through a reaction group as described above.

[0274] Furthermore, the final product formed by reductive alkylation via an aldehyde bond is much more stable than that formed via an amide bond. The aldehyde reactive group reacts selectively at the N-terminus at low pH, and can form a covalent bond with lysine residues at high pH, ​​such as pH 9.0.

[0275] In addition, the reactive groups at both ends of the linker may be the same or different, for example, it may have an aldehyde group at both ends, or it may have a maleimide group at one end and an aldehyde group, propionaldehyde group, or butyraldehyde group at the other end. However, it is not particularly limited thereto, as long as F, specifically an immunoglobulin Fc region and X, can be bound to each end of the linker.

[0276] For example, one end of the linker may include a maleimide group as a reactive group, and the other end may include an aldehyde group, a propionaldehyde group, a butyraldehyde group, or the like.

[0277] When polyethylene glycol having hydroxy reactive groups at both ends is used as a linker, the interleukin 2 analog long-acting conjugate of the present invention can be prepared by activating the hydroxy groups into various reactive groups through a known chemical reaction, or by using polyethylene glycol having a commercially available modified reactive group.

[0278] In one specific embodiment, the linker may be linked to a cysteine ​​residue of X, more specifically, but not limited to, a -SH group of the cysteine.

[0279] Specifically, the reactive group of the linker can be linked to the -SH group of the cysteine ​​residue, and all of the above-described reactive groups are applicable. If maleimide-PEG-aldehyde is used, the maleimide group can be linked to the -SH group of X via a thioether bond, and the aldehyde group can be linked to F, specifically the -NH2 group of immunoglobulin Fc, via a reductive amination reaction, but is not limited thereto.

[0280] In another specific embodiment, the linker may be linked to a lysine residue of X, more specifically, to an amino group of the lysine, but is not limited thereto.

[0281] Additionally, in the above complex, the reactive group of the linker may be linked to -NH2 located at the N-terminus of the immunoglobulin Fc region, but is not limited thereto.

[0282] Additionally, in the above conjugate, the interleukin 2 analog according to the present invention may be linked to a linker having a reactive group via the C-terminus, but this is only one example.

[0283] In the present invention, "C-terminus" refers to the carboxyl terminus of a peptide, and for the purposes of the present invention, refers to a position capable of binding to a linker. For example, but not limited to, it may include not only the most terminal amino acid residue of the C-terminus but also all amino acid residues surrounding the C-terminus, and specifically, it may include, but is not limited to, the first to 20th amino acid residues from the most terminal.

[0284]

[0285] In addition, the above-described combination may have an increased duration of effect compared to X in which F is not modified, and such combination includes not only the above-described form but also a form encapsulated in biodegradable nanoparticles.

[0286]

[0287] The interleukin 2 analog long-acting conjugate of the present invention may have an interleukin 2 alpha receptor binding affinity that is completely lost, or about 0.001 times or more, about 0.005 times or more, about 0.01 times or more, about 0.05 times or more, about 0.1 times or more, about 0.3 times or more, about 0.5 times or more, about 0.6 times or more, about 0.7 times or more, about 0.8 times or more, about 0.9 times or more, about 1.1 times or more, about 1.3 times or more, about 1.5 times or more, or about 1.7 times or more, compared to the interleukin 2 alpha receptor binding affinity of a natural interleukin 2, aldesleukin, or a long-acting conjugate comprising the same, but the numerical value is not limited, and if the binding affinity is changed compared to the natural interleukin 2 or aldesleukin, it falls within the scope of the present invention.

[0288] In addition, specifically, the interleukin 2 analog long-acting conjugate of the present invention may have an interleukin 2 beta receptor binding affinity of about 0.1 times or more, about 0.3 times or more, about 0.5 times or more, about 0.7 times or more, about 1.0 times or more, about 10 times or more, about 20 times or more, about 30 times or more, about 40 times or more, about 50 times or more, about 60 times or more, about 70 times or more, about 80 times or more, about 90 times or more, about 100 times or more, about 130 times or more, about 150 times or more, or about 200 times or more compared to the interleukin 2 beta receptor binding affinity of natural interleukin 2, aldesleukin, or a long-acting conjugate comprising the same, but the numerical value is not limited, and if the binding affinity is changed or increased compared to natural interleukin 2 or aldesleukin, it falls within the scope of the present invention.

[0289]

[0290] Unless otherwise indicated herein, the description in the specification or claims of the "interleukin 2 analog" or the "conjugate" in which the interleukin 2 analog is covalently linked to a biocompatible material according to the present invention applies to a category that includes not only the interleukin 2 analog or the conjugate, but also a salt of the interleukin 2 analog or the conjugate (e.g., a pharmaceutically acceptable salt of the interleukin 2 analog), or a solvate thereof. Therefore, even if the specification describes only "interleukin 2 analog" or "conjugate," the description also applies to the specific salt, the specific solvate, or the specific solvate of the specific salt. The salt form may be, for example, a form using any pharmaceutically acceptable salt. The type of the salt is not particularly limited. However, it is preferable that it is a form that is safe and effective for a subject, such as a mammal, but is not particularly limited thereto.

[0291] The type of the above salt is not particularly limited. However, it is preferable that it be in a form that is safe and effective for an individual, such as a mammal, but is not particularly limited thereto.

[0292] The above term, “pharmaceutically acceptable” means a substance that can be effectively used for the intended purpose without causing excessive toxicity, irritation, or allergic reaction within the scope of pharmaceutical judgment.

[0293] As used herein, the term "pharmaceutically acceptable salt" includes salts derived from pharmaceutically acceptable inorganic acids, organic acids, or bases. Examples of suitable acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like. Salts derived from suitable bases may include alkali metals such as sodium and potassium, alkaline earth metals such as magnesium, and ammonium.

[0294] Additionally, the term "solvate" used in the present invention refers to an interleukin 2 analog or salt thereof according to the present invention formed in a complex with a solvent molecule.

[0295]

[0296] The composition according to the present invention may be a composition comprising the interleukin 2 analog or a sustained-acting conjugate thereof, and specifically, may be a pharmaceutical composition having a purpose of preventing or treating cancer, and may be administered in combination with an immune checkpoint inhibitor or a composition comprising the same. The interleukin 2 analog or a sustained-acting conjugate thereof is as described above. More specifically, the composition may comprise a pharmacologically effective amount of an interleukin 2 analog or a sustained-acting conjugate thereof, and further comprise a pharmaceutically acceptable carrier, and may be administered in combination with a pharmacologically effective amount of an immune checkpoint inhibitor or a composition comprising the same.

[0297] Alternatively, the composition of the present invention may further comprise, but is not limited to, an immune checkpoint inhibitor.

[0298]

[0299] As a specific example of the composition according to the present invention, it may include an interleukin 2 analog comprising any one amino acid sequence selected from the group consisting of SEQ ID NOs: 3 to 106 or a sustained-release conjugate thereof, and more specifically, it may include an interleukin 2 analog comprising any one amino acid sequence selected from the group consisting of SEQ ID NOs: 22, 42, 53, 87, 105, and 106 or the interleukin 2 analog or a sustained-release conjugate thereof, and may be administered in combination with an immune checkpoint inhibitor or a composition comprising the same, but is not limited thereto.

[0300]

[0301] The composition comprising the interleukin 2 analog or interleukin 2 analog long-acting conjugate of the present invention may be administered concurrently, sequentially, or in reverse order with a composition comprising an immune checkpoint inhibitor, but is not limited thereto.

[0302] In the present invention, the term "pharmacologically effective amount" refers to a safe dosage that exhibits a cancer prevention or treatment effect of the interleukin 2 analog or its long-acting conjugate; and an immune checkpoint inhibitor without causing toxicity or side effects to the patient. Specifically, it may refer to a dosage that can exhibit significant activity at the interleukin 2 receptor (e.g., beta and / or alpha receptor) or a dosage that can activate T cells, but is not limited thereto.

[0303]

[0304] The composition according to the present invention may exhibit one or more of the following properties, but is not limited thereto, as long as it exhibits an increased immune response and an anticancer effect:

[0305] (i) Higher blood exposure compared to aldesleukin alone or in combination with an immune checkpoint inhibitor;

[0306] (ii) Superior tumor growth inhibition compared to aldesleukin alone or combined administration of aldesleukin and an immune checkpoint inhibitor;

[0307] (iii) Superior memory T cell generation response compared to aldesleukin alone or combined administration of aldesleukin and immune checkpoint inhibitors.

[0308] (iv) superior inhibition of immune checkpoint protein activation compared to aldesleukin alone or in combination with aldesleukin and an immune checkpoint inhibitor; and

[0309] (v) Superior T cell activation compared to aldesleukin alone or combined administration of aldesleukin and immune checkpoint inhibitors.

[0310]

[0311] Interleukin 2, also known as T-cell growth factor, is a protein involved in immune regulation. It promotes T-cell proliferation, stimulates B cells, and acts on T cells to secrete γ-interferon. Based on this immunoregulatory activity of interleukin 2, cancer prevention and treatment can be achieved by utilizing the body's immune system to eliminate cancer cells.

[0312] In particular, the interleukin 2 analog of the present invention has an enhanced binding affinity for the interleukin 2 beta receptor, which plays a major role in signal transduction, which leads to a more effective anticancer effect in the immune system of the subject. In addition, the sustained conjugate comprising the interleukin 2 analog has an enhanced binding affinity for the interleukin 2 beta receptor, and while the duration is increased, the blood exposure is increased, resulting in excellent bioavailability, and ultimately, excellent tumor growth inhibition ability, which can exhibit an effective cancer prevention or treatment effect. In addition, it has an excellent memory T cell production ability, which can exhibit an effect of suppressing cancer recurrence through the immune memory response of the subject, and thus can be utilized as a safe and effective cancer treatment agent.

[0313]

[0314] When an immune checkpoint inhibitor is used together with an interleukin 2 analog according to the present invention, an excellent combination administration effect can be obtained by enabling the immune checkpoint inhibitor to attack cancer cells that evade immunity by activating T cells and thereby utilizing the immune checkpoint of T cells.

[0315] In the present invention, “immune checkpoint inhibitor” refers to a therapeutic agent that activates T cells to attack cancer cells by binding to an immune checkpoint protein involved in T cell suppression and blocking its activity.

[0316] The above immune checkpoint inhibitor refers to a therapeutic agent that maintains the function of original immune cells (e.g., T cells) by preventing the binding of immune checkpoint proteins (e.g., PD-1) and ligands (e.g., PD-L1) of cancer cells.

[0317] The above immune checkpoint inhibitors may include, but are not limited to, peptides, antibodies or antigen-binding fragments thereof, nucleic acid molecules, and small molecules, as long as they are capable of antagonizing action.

[0318] An example of an immune checkpoint inhibitor of the present invention may include an anti-PD-1 antibody or an antigen-binding fragment thereof.

[0319]

[0320] PD-1 (programmed cell death-1) is the best-known immune checkpoint protein. It exists on the outside of immune cells and can specifically bind to the PD-L1 (programmed death-ligand 1) protein on various cells in the body. When PD-L1 binds to PD-1, immune cell function is inactivated, suppressing the immune response and preventing unnecessary autoimmune reactions. However, cancer cells can express large amounts of PD-L1 on their surface, allowing them to bind to PD-1 on immune cells, thereby inhibiting T cell function and preventing the body's immune response. In this case, cancer cells can evade the immune response and survive.

[0321]

[0322] The immune checkpoint inhibitor of the present invention can exert an anticancer effect by utilizing the body's immune response by antagonizing the immune checkpoint protein that cancer cells use to evade immunity, thereby enabling an appropriate immune response to neutralize cancer cells.

[0323]

[0324] In the present invention, the anti-PD-1 (programmed cell death-1) antibody may be selected from the group consisting of nivolumab, pembrolizumab, cemiplimab, spartalizumab, camrelizumab, sintilimab, tislelizumab, toripalimab, dostarlimab, INCMGA00012, AMP-224, and AMP-514, but is not limited thereto.

[0325]

[0326] The pharmaceutical composition for preventing or treating cancer comprising the interleukin 2 analog or a long-acting conjugate thereof of the present invention may be administered in combination with an immune checkpoint inhibitor or a composition comprising the same, thereby exhibiting excellent anticancer efficacy while reducing side effects through the synergistic action of the interleukin 2 analog or a long-acting conjugate thereof and the immune checkpoint inhibitor.

[0327]

[0328] Immune checkpoint inhibitors are known to have different responsiveness depending on the phenotype of the tumor microenvironment (TME). However, their responsiveness is very low in immune-impermeable tumors (cold tumors), which limits their use as cancer treatments.

[0329] The interleukin 2 analog or its long-acting conjugate of the present invention can induce a transformation from an immune-impermeable tumor to an invasive tumor (hot tumor) by altering the tumor microenvironment, which is less responsive to immune checkpoint inhibitors. Therefore, excellent therapeutic effects can be achieved when an immune checkpoint inhibitor is co-administered with the interleukin 2 analog or its long-acting conjugate.

[0330]

[0331] PD-1 (programmed cell death-1), one of the immune checkpoint proteins, exists on the outside of immune cells and can specifically bind to the PD-L1 (programmed death-ligand 1) protein on various cells in the human body.

[0332] The pharmaceutical composition for preventing or treating cancer comprising the interleukin 2 analog or a long-acting conjugate thereof of the present invention can more effectively treat cancer having low responsiveness to a PD-1 antagonist, but is not limited thereto.

[0333] In the present invention, the cancer is renal cell carcinoma, melanoma, colon cancer, liver cancer, uterine cancer, ovarian cancer, pancreatic cancer, gallbladder cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, skin cancer, breast cancer, bladder cancer, stomach cancer, head or neck cancer, esophageal cancer, laryngeal cancer, bone cancer, rectal cancer, anal cancer, colon cancer, fallopian tube carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, small intestine cancer, endocrine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, renal pelvic carcinoma, CNS tumor, primary CNS lymphoma, spinal cord tumor, brain tumor, glioma (astrocytoma, glioblastoma, oligodendroglioma) May include, but are not limited to, ependymoma, germ cell tumor, meningioma, brainstem glioma, pituitary adenoma, schwannoma, congenital tumor, craniopharyngioma, or brain tumor.

[0334] Specifically, the cancer may be any one selected from the group consisting of colon cancer, liver cancer, ovarian cancer, pancreatic cancer, gallbladder cancer, kidney cancer, lung cancer, skin cancer, melanoma, breast cancer, bladder cancer, and stomach cancer. Alternatively, the cancer according to the present invention may be a primary cancer, a recurrent cancer, or a metastatic cancer, but is not limited thereto. It may also include metastatic renal cell carcinoma or metastatic melanoma. More specifically, the cancer may be a cancer type that is low in response to a PD-1 antagonist.

[0335]

[0336] Although not particularly limited thereto, the pharmaceutical composition of the present invention may contain 0.01 to 99% weight to volume of an interleukin 2 analog or a long-acting conjugate thereof.

[0337] Specifically, the composition of the present invention may include, but is not limited to, an interleukin 2 analog or a long-acting conjugate thereof; and an immune checkpoint inhibitor, each administered at 0.00001 mg / mL to 100 mg / mL.

[0338] More specifically, the composition of the present invention may comprise a sustained-release conjugate of an interleukin 2 analog in an amount of 0.0001 to 2120 mg / kg, and an immune checkpoint inhibitor may be administered in combination with the sustained-release conjugate of the interleukin 2 analog in an amount of 0.0001 to 1000 mg / kg, but is not limited thereto. Alternatively, the composition of the present invention may comprise a sustained-release conjugate of an interleukin 2 analog in an amount of 0.00005 to 500 mg / kg, and an immune checkpoint inhibitor may be administered in combination with the interleukin 2 analog in an amount of 0.0001 to 1000 mg / kg, but is not limited thereto.

[0339] However, the dosage of the immune checkpoint inhibitor may be changed so as to exhibit an excellent co-administration effect with the interleukin 2 analog or long-acting conjugate thereof of the present invention.

[0340] For example, the dose of the immune checkpoint inhibitor of the composition of the present invention may be expressed based on the PD-1 inhibitor, and when including another immune checkpoint inhibitor, the immune checkpoint inhibitor may be included in a dose corresponding to the dosage of the PD-1 inhibitor, but is not limited thereto.

[0341] In addition, the interleukin 2 analog or its long-acting conjugate and the immune checkpoint inhibitor included in the composition of the present invention may be administered in appropriately divided doses, and the doses may be the same or different. For example, when the interleukin 2 analog or its long-acting conjugate of the composition is administered once per week, the immune checkpoint inhibitor may be administered once, twice, or more times per week, but is not limited thereto.

[0342]

[0343] In the present invention, the term "prevention" means any act of inhibiting or delaying cancer or tumor by administering the interleukin 2 analog (e.g., the interleukin 2 analog itself or a sustained-release conjugate form in which a biocompatible material is bound to the interleukin 2 analog) or a composition containing the same; and an immune checkpoint inhibitor or a composition containing the same.

[0344] In the present invention, the term "treatment" means any action that improves or benefits the symptoms of cancer by administering the interleukin 2 analog (e.g., the interleukin 2 analog itself or a sustained-release conjugate form in which a biocompatible material is bound thereto) or a composition containing the same; and an immune checkpoint inhibitor or a composition containing the same.

[0345] The use of the interleukin 2 analog or its long-acting conjugate and the immune checkpoint inhibitor of the present invention has a great advantage in that it can improve the quality of life of chronic patients who need to be administered daily by reducing the number of administrations due to a dramatic increase in blood exposure, blood half-life, and in vivo efficacy duration.

[0346]

[0347] The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier or diluent. Such pharmaceutically acceptable carrier or diluent may be non-naturally occurring.

[0348]

[0349] In the present invention, the term "pharmaceutically acceptable" means a sufficient amount to exhibit a therapeutic effect and not causing side effects, and can be easily determined by those skilled in the art based on factors well known in the medical field, such as the type of cancer, the patient's age, weight, health, sex, the patient's sensitivity to drugs, administration route, administration method, number of administrations, treatment period, and drugs used in combination or simultaneously.

[0350] The pharmaceutical composition comprising the interleukin 2 analog or its sustained-release conjugate of the present invention or an immune checkpoint inhibitor may include a pharmaceutically acceptable excipient. The excipient is not particularly limited thereto, but may include a binder, a lubricant, a disintegrant, a solubilizer, a dispersant, a stabilizer, a suspending agent, a pigment, a fragrance, etc. for oral administration, and may include a mixture of buffers, preservatives, analgesics, solubilizers, isotonic agents, stabilizers, etc. for injections, and may include a base, excipients, lubricants, preservatives, etc. for topical administration.

[0351] The composition of the present invention can be prepared in various forms by mixing it with the pharmaceutically acceptable excipients described above. For example, for oral administration, it can be prepared in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, etc., and for injections, it can be prepared in the form of unit dose ampoules or multiple doses. In addition, it can be formulated in the form of solutions, suspensions, tablets, pills, capsules, sustained-release preparations, etc.

[0352] Meanwhile, examples of carriers, excipients, and diluents suitable for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, or mineral oil. In addition, fillers, anticoagulants, lubricants, wetting agents, fragrances, preservatives, and the like may be additionally included.

[0353] In addition, the pharmaceutical composition of the present invention may have any one dosage form selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquids, emulsions, syrups, sterilized aqueous solutions, non-aqueous solutions, lyophilized preparations, and suppositories.

[0354] In addition, the composition is formulated into a unit dosage form suitable for administration into a patient's body according to a conventional method in the pharmaceutical field, specifically, into a form of a formulation useful for administration of a protein drug, and can be administered by a parenteral route including, but not limited to, oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, intragastric, topical, sublingual, vaginal, or rectal route using an administration method conventionally used in the art.

[0355] Additionally, the above complex may be used in combination with various carriers acceptable as pharmaceuticals, such as saline or organic solvents, and carbohydrates such as glucose, sucrose or dextran, antioxidants such as ascorbic acid or glutathione, chelating agents, low-molecular-weight proteins or other stabilizers may be used as pharmaceuticals to increase stability or absorbability.

[0356]

[0357] Another aspect of the present invention provides a method for preventing or treating cancer, comprising administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-2 analog or a long-acting conjugate thereof, in combination with an immune checkpoint inhibitor or a composition comprising the same. In the method, the pharmaceutical composition comprising an interleukin-2 analog or a long-acting conjugate thereof and the immune checkpoint inhibitor or a composition comprising the same may be administered simultaneously, sequentially, or in reverse order, but is not limited thereto.

[0358] The interleukin 2 analogue and / or the long-acting combination of the interleukin 2 analogue, the immune checkpoint inhibitor, the composition containing them, and the prevention and treatment of cancer are as described above.

[0359] Another embodiment of the present invention is a method for preventing or treating cancer, comprising administering to a subject in combination an interleukin 2 analog or a long-acting complex comprising the same, and an immune checkpoint inhibitor.

[0360] The method may be, but is not limited to, administering to a subject a composition comprising an interleukin 2 analog or a long-acting conjugate comprising the same, and an immune checkpoint inhibitor, or co-administering an interleukin 2 analog or a long-acting conjugate comprising the same, and an immune checkpoint inhibitor as separate formulations.

[0361] The method of the present invention may be, but is not limited to, administering (i) an interleukin 2 analog or a long-acting conjugate comprising the same and (ii) an immune checkpoint inhibitor as a single formulation, or administering individual formulations simultaneously, separately, sequentially, or in reverse order.

[0362] The interleukin 2 analog or a long-acting conjugate comprising the same, an immune checkpoint inhibitor, a composition, cancer, prevention, and treatment are as described above.

[0363]

[0364] In the present invention, the subject is a subject that has developed or is suspected of having cancer, and refers to a mammal including a human, a mouse, a livestock, etc., but a subject that can be treated with the interleukin 2 analog and / or conjugate of the present invention, an immune checkpoint inhibitor, or a composition containing them is included without limitation.

[0365] In the present invention, the term "administration" means introducing a given substance (e.g., an interleukin 2 analog or a long-acting conjugate thereof, or an immune checkpoint inhibitor) to a patient by any appropriate method, and the route of administration is not particularly limited thereto, but may be administered through any general route capable of reaching an in vivo target, for example, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration, or rectal administration.

[0366]

[0367] The method of the present invention may include administering a pharmaceutically effective amount of a pharmaceutical composition comprising the interleukin-2 analog or a long-acting conjugate thereof, and administering a pharmaceutically effective amount of an immune checkpoint inhibitor or a pharmaceutical composition comprising the same. An appropriate total daily dose may be determined by a treating physician within the scope of sound medical judgment, and may be administered once or in several divided doses. However, for the purpose of the present invention, it is preferable that a specific therapeutically effective amount for a specific patient be applied differently depending on various factors including the type and degree of response to be achieved, the specific composition including whether other agents are used in some cases, the patient's age, weight, general health condition, sex, and diet, the time of administration, the route of administration, and the secretion rate of the composition, the treatment period, drugs used together or concurrently with the specific composition, and similar factors well known in the medical field.

[0368]

[0369] In the method of the present invention, the dosage and frequency of administration are determined based on the type of drug as the active ingredient, along with various related factors such as the disease to be treated, the route of administration, the patient's age, sex, and weight, and the severity of the disease. Specifically, the composition of the present invention may comprise, but is not limited to, a pharmaceutically effective amount of the interleukin 2 analog or a long-acting conjugate comprising the same, and an immune checkpoint inhibitor.

[0370] The inclusion of the interleukin 2 analog or long-acting conjugate and immune checkpoint inhibitor in a pharmaceutically effective amount means the extent to which the desired pharmacological activity (e.g., prevention, improvement, or treatment of cancer) can be obtained due to the interleukin 2 analog or long-acting conjugate and immune checkpoint inhibitor, and may also mean a pharmaceutically acceptable level in which no toxicity or side effects occur or are minimal in the administered subject, but is not limited thereto. Such a pharmaceutically effective amount may be determined in comprehensive consideration of the number of administrations, patients, formulation, etc.

[0371] Although not particularly limited thereto, the pharmaceutical composition of the present invention may contain the above-mentioned ingredient (active ingredient) in an amount of 0.01 to 99% by weight to volume.

[0372]

[0373] The total effective amount of the composition of the present invention can be administered to a patient as a single dose, or can be administered by a fractionated treatment protocol in which multiple doses are administered over a long period of time. The pharmaceutical composition of the present invention may vary the content of the active ingredient depending on the severity of the disease. Specifically, a preferred total dose of the interleukin 2 analog or its long-acting conjugate and the immune checkpoint inhibitor co-administered according to the present invention may be about 0.0001 mg to 500 mg per kg of patient body weight per day. However, the dose of the interleukin 2 analog or its conjugate and the immune checkpoint inhibitor is determined by taking into consideration various factors such as the route of administration and the number of treatments of the pharmaceutical composition, as well as the patient's age, weight, health status, sex, severity of the disease, diet, and excretion rate. Therefore, considering these points, a person having ordinary skill in the art will be able to determine an appropriate effective dosage according to a specific use of the composition of the present invention. The pharmaceutical composition according to the present invention is not particularly limited in its formulation, administration route, and administration method as long as it exhibits the effects of the present invention.

[0374] The pharmaceutical composition of the present invention exhibits excellent in vivo persistence and potency, thereby significantly reducing the number and frequency of administration of the pharmaceutical preparation of the present invention. The pharmaceutical composition may be administered via intraperitoneal, intravenous, intramuscular, subcutaneous, intradermal, oral, topical, intranasal, intrapulmonary, or rectal routes, but is not limited to a specific route of administration as long as the desired pharmacological effect can be achieved.

[0375] For example, the pharmaceutical composition of the present invention may be administered once a week, once every two weeks, once every three weeks, once every four weeks, or once a month, or may be administered once or multiple times at time intervals ranging from one week to one month, but is not limited thereto.

[0376] Specifically, the interleukin 2 analog or its long-acting conjugate and the immune checkpoint inhibitor may be administered at a dose of about 0.00001 mg or more per kg of patient body weight per week, respectively, and 0.0000001 mg or more per kg of patient body weight per week, and when the two substances are used together, the total dose may be administered at a dose of about 0.00001 mg or more per kg of patient body weight per week, but is not limited thereto.

[0377] Specifically, the method of the present invention may be, but is not limited to, administering 0.00001 to 175 mg of the interleukin-2 analog long-acting conjugate and 0.0000001 to 100 mg of the immune checkpoint inhibitor per 1 kg of the patient's body weight per week. Alternatively, the method of the present invention may be, but is not limited to, administering 0.000001 to 50 mg of the interleukin-2 analog and 0.0000001 to 100 mg of the immune checkpoint inhibitor per 1 kg of the patient's body weight per week.

[0378] Alternatively, the method of the present invention may be, but is not limited to, administering an interleukin 2 analog or a long-acting conjugate thereof at 0.001 to 33,000 nmol / kg and an immune checkpoint inhibitor at 0.0001 to 7,000 nmol / kg for one week.

[0379] Additionally, the interleukin 2 analog or its long-acting conjugate and the immune checkpoint inhibitor of the present invention may be administered in appropriately divided doses, and the doses may be the same or different. For example, when the interleukin 2 analog or its long-acting conjugate is administered once per week, the immune checkpoint inhibitor may be administered once, twice, or more times per week, but is not limited thereto.

[0380]

[0381] However, the dosage of the immune checkpoint inhibitor may be changed so as to exhibit an excellent co-administration effect with the interleukin 2 analog or long-acting conjugate thereof of the present invention.

[0382] For example, the dosage of the above immune checkpoint inhibitor may be expressed based on the PD-1 inhibitor, and in the case of other immune checkpoint inhibitors, it may be administered in a dosage corresponding to the dosage of the PD-1 inhibitor, but is not limited thereto.

[0383]

[0384] Another embodiment of the present invention is the use of the interleukin 2 analog or a long-acting conjugate thereof for the manufacture of a medicament for the prevention or treatment of cancer; or a composition comprising the same, wherein the composition is administered in combination with an immune checkpoint inhibitor.

[0385] Another embodiment of the present invention is the combined use of an interleukin 2 analog or a long-acting conjugate thereof and an immune checkpoint inhibitor for the prevention or treatment of cancer.

[0386] The interleukin 2 analog and / or its long-acting conjugate, immune checkpoint inhibitor, or composition containing them, cancer, prevention, treatment, administration route and number of administrations are as described above.

[0387]

[0388] Another embodiment of the present invention provides a composition comprising an interleukin 2 analog or a long-acting conjugate thereof; or a composition comprising the same, wherein the composition is administered in combination with an immune checkpoint inhibitor for the purpose of preventing or treating cancer.

[0389] The interleukin 2 analog and / or its long-acting conjugate, immune checkpoint inhibitor, or composition containing them, cancer, prevention, treatment, administration route and number of administrations are as described above.

[0390]

[0391] Meanwhile, unless the context otherwise requires in this specification, it should be understood that the expressions “includes,” “including,” “containing,” etc. mean the inclusion of a specified integer or group of integers, but not the exclusion of other integers or sets of integers.

[0392]

[0393] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention more specifically, and the scope of the present invention is not limited by these examples.

[0394]

[0395] Example 1: Production of native interleukin 2 and interleukin 2 analog expression vectors

[0396]

[0397] To construct a native interleukin 2 expression vector encoding 133 amino acids, interleukin 2 synthesized based on the reported interleukin 2 sequence (NM_000586.3; SEQ ID NO: 1) was cloned into the pET-22b vector (Novagen). In addition, a novel interleukin 2 analog was constructed using the interleukin 2 as a template, in which the amino acids of interleukin 2 were modified.

[0398] PCR conditions for amplification of interleukin 2 analogs were 95°C for 30 seconds, 55°C for 60 seconds, and 65°C for 6.5 minutes, with this process repeated 16 times. Sequence analysis was performed on the mutagenesis products obtained under the above conditions, and it was confirmed that each interleukin 2 analog had a mutation at the target mutation position based on the native type, as shown in Table 1 below. The expression vectors thus obtained were named pET22b-interleukin 2 analogs 1 to 105.

[0399] The sequence of each amino acid change and analog name are shown in Table 1 below. To produce these interleukin 2 analogs, each analog gene was amplified by PCR using forward (F) and reverse (R) primers.

[0400] In Table 1 below, analog 1 is aldesleukin, and primers #1 to #204 correspond to sequence numbers 214 to 417, respectively. Table 1 summarizes the types of interleukin 2 analogs, mutation locations, and their altered sequences.

[0401]

[0402]

[0403]

[0404]

[0405]

[0406]

[0407]

[0408]

[0409]

[0410]

[0411]

[0412] desA1 means deletion of alanine, the first amino acid of interleukin-2. Table 2 below shows the full-length protein sequences of interleukin-2 analogs. Bold text in Table 2 below indicates the mutation location. Table 2 summarizes the amino acid sequences of interleukin-2 analogs.

[0413]

[0414]

[0415]

[0416]

[0417]

[0418]

[0419]

[0420]

[0421]

[0422]

[0423]

[0424]

[0425] Example 2: Expression of interleukin 2 analogues

[0426]

[0427] Using the expression vector prepared in Example 1, recombinant interleukin 2 analogs were expressed under the control of the T7 promoter. Each recombinant interleukin 2 analog expression vector was expressed in an E. coli strain, E. coli BL21DE3 (E. coli B F - dcmompThsdS(r B - m B -)galλ(DE3); Novagen) was transformed. The transformation method recommended by Novagen was used. Each single colony transformed with each recombinant expression vector was taken, inoculated into 2X Luria Broth medium containing ampicillin (50 μg / mL), and cultured at 37°C for 15 h. The recombinant strain culture medium and 2X LB medium containing 30% glycerol were mixed at a ratio of 1:1 (v / v), and 1 mL each was dispensed into cryotubes and stored at -150°C. This was used as a cell stock for the production of recombinant proteins.

[0428] For expression of recombinant interleukin-2 analogs, one vial of each cell stock was thawed and inoculated into 500 mL of 2X LB, and cultured with shaking at 37°C for 14 to 16 hours. When the absorbance value at 600 nm was 4.0 or higher, the culture was terminated and used as the seed culture. Using a 5 L fermenter (Bioflo-320, NBS, USA), the seed culture was inoculated into 1.6 L of fermentation medium, and initial fermentation was started. The culture conditions were 37°C, 2.0 L / min (1 vvm) of air, 650 rpm of stirring speed, and 30% ammonia water, and the pH was maintained at 6.7. When the nutrients in the culture medium became limited, fed-batch culture was performed by adding additional medium (feeding solution). Strain growth was monitored by OD values, and IPTG was introduced at a final concentration of 500 μM when the absorbance value was 70 or higher. Cultivation was continued for approximately 23 to 25 hours after IPTG introduction, and after completion of cultivation, the recombinant strain was harvested using a centrifuge and stored at -80°C until use.

[0429]

[0430] Example 3: Extraction and refolding of interleukin 2 analogues

[0431]

[0432] To convert the interleukin-2 analog obtained from the E. coli expressing the interleukin-2 analog obtained in Example 2 into a soluble form, the cells were disrupted and refolding was induced. The cell pellet corresponding to 100 mL of culture medium was suspended in 1-200 mL of disruption buffer (20 mM Tris-HCl pH 9.0, 1 mM EDTA pH 9.0, 0.2 M NaCl, 0.5% Triton X-100), and the recombinant E. coli was disrupted at 15,000 psi using a microfluidizer. The supernatant was discarded after centrifugation at 13,900 g for 30 minutes, and the pellet was washed with 400 mL of the first wash buffer (50 mM Tris-HCl pH 8.0, 5 mM EDTA pH 9.0). Centrifugation was performed under the same conditions as above, the supernatant was discarded, and the pellet was washed with 400 mL of a second wash buffer solution (50 mM Tris-HCl pH 8.0, 5 mM EDTA pH 9.0, 2% Triton X-100). Centrifugation was performed under the same conditions as above, the supernatant was discarded, and the pellet was washed with 400 mL of a third wash buffer solution (50 mM Tris-HCl pH 8.0, 5 mM EDTA pH 9.0, 1% sodium deoxycholorate). Centrifugation was performed under the same conditions as above, the supernatant was discarded, and the pellet was washed with 400 mL of a fourth wash buffer solution (50 mM Tris-HCl pH 8.0, 5 mM EDTA pH 9.0, 1 M NaCl). The washed E. coli inclusion body pellet was obtained by centrifugation under the same conditions as above. The washed inclusion body pellet was resuspended in 400 mL of solubilizing / reducing buffer (6 M Guanidine, 100 mM Tris pH 8.0, 2 mM EDTA pH 9.0, 50 mM DTT) and stirred at 50°C for 30 min. 100 mL of distilled water was added to the solubilized / reduced interleukin-2 analog to dissolve 6 M Guanidine in 4.After diluting with 8 M Guanidine, centrifugation was performed at 13,900 g for 30 minutes to discard the pellet and obtain only the solution. 185.7 mL of distilled water was additionally added to the diluted solution to dilute 4.8 M Guanidine to 3.5 M Guanidine, and the pH was adjusted to 5.0 using 100% acetic acid. The pH-adjusted solution was stirred at room temperature for 1 hour. The solution in which impurities had precipitated was centrifuged at 13,900 g for 30 minutes, the supernatant was discarded, and the pellet was washed with the final wash buffer solution (3.5 M Guanidine, 20 mM Sodium Acetate pH 5.0, 5 mM DTT). Centrifugation was performed under the same conditions as above to obtain a pellet. The washed interleukin-2 analog was dissolved in 400 mL of refolding buffer (6 mM Guanidine, 100 mM Tris pH 8.0, 0.1 mM CuCl2). The refolding process was performed by stirring the mixed solution at 4°C for 15 to 24 hours.

[0433]

[0434] Example 4: Size exclusion column chromatography

[0435]

[0436] The interleukin-2 analog refolding solution obtained in Example 3 was concentrated to less than 1 mL for purification by applying it to a size exclusion column. The column was equilibrated with a buffer solution (2 M Guanidine, 100 mM Tris pH 8.0) before introducing the refolding solution, and eluted by flowing the buffer solution after introducing the refolding solution. The eluted sample contained guanidine, so it was replaced with a stabilizing solution (10 mM Sodium Acetate pH 4.5, 5% Trehalose), and the purity was measured through RP-HPLC and peptide mapping analysis. If the measured purity was 80% or higher, it was used in the experiment.

[0437]

[0438] Example 5: Evaluation of receptor binding affinity of interleukin 2 analogs

[0439]

[0440] Surface plasmon resonance (SPR, BIACORE T200, GE healthcare) was used to measure the receptor binding affinity of the interleukin 2 analog obtained in Example 4 to the interleukin 2 alpha receptor and beta receptor, respectively. The binding affinity of the manufactured analog to the alpha receptor and beta receptor was measured, and each binding affinity was compared with that of interleukin 2 analog 1 (aldesleukin).

[0441]

[0442] First, about 5,000 RU (resonance units) of anti-human immunoglobulin antibody (Abcam, #ab97221) was immobilized on a CM5 chip (GE Healthcare) through the amine coupling method, and then the human immunoglobulin Fc region-bound interleukin 2 alpha receptor (SYMANSIS, #4102H) or interleukin 2 beta receptor (SYMANSIS, #4122H) was bound to the immunoglobulin antibody using an antigen-antibody binding reaction, and then finally immobilized. Next, the recombinant interleukin 2 analog prepared above was diluted in HBS-P+ buffer (Cytiva, BR100671) by a two-fold serial dilution method at each concentration, and the mixture was flowed through the CM5 chip on which the interleukin 2 receptor was finally immobilized, and the binding affinity of each interleukin 2 receptor was measured. The binding affinity was expressed as the association rate (K a ) and the Harry velocity (K d) was used to measure the binding rate by flowing interleukin 2 analog for 3 minutes at a flow rate of 10 uL / min, and the dissociation rate from each interleukin 2 receptor was measured by flowing only HBS-P+ buffer at the same time and flow rate. Upon completion of the measurement, the binding affinity of the receptor was evaluated according to the 1:1 binding fitting model in the Biaevaluation program.

[0443]

[0444] Relative binding strength K D (%) = Analog 1 (aldesleukin) dissociation constant (K d ) / Analog dissociation constant (K d ) × 100

[0445]

[0446] In Table 3 below, “Undefined” indicates that the physical quantity cannot be defined for that receptor because no binding to that receptor was observed in surface plasmon resonance measurements. Table 3 summarizes the relative binding affinity of interleukin-2 analogs to interleukin-2 alpha or beta receptors compared to interleukin-2 analog 1 (aldesleukin).

[0447]

[0448]

[0449]

[0450]

[0451]

[0452] As specified in the test results above (Table 3), it was confirmed that the interleukin 2 analogs of the present invention exhibited interleukin 2 alpha receptor binding affinity that was different from that of natural interleukin 2 or aldesleukin, such as completely losing interleukin 2 alpha receptor binding affinity or decreasing or increasing it compared to interleukin 2 analog 1. On the other hand, a stronger binding affinity was confirmed for the interleukin 2 beta receptor than that of natural interleukin 2 or aldesleukin. This confirmed that the amino acid sequence of the interleukin 2 analog influenced the binding of the interleukin 2 alpha or beta receptor. This suggests that the binding affinity of the interleukin 2 receptor can be changed by substituting an amino acid at a specific position.

[0453] The above experimental results suggest that the interleukin 2 analog according to the present invention has changed interleukin 2 alpha receptor binding affinity and interleukin 2 beta receptor binding affinity, and can be used to develop various drugs using the same.

[0454]

[0455] Example 6: Linkage reaction of interleukin 2 analog and polyethylene glycol (3.4K PEG) linker and purification of interleukin 2 analog linker

[0456]

[0457] In order to prepare a sustained conjugate in which the interleukin 2 analog obtained in Example 4 is bound to the immunoglobulin Fc region, a conjugate was first prepared in which the interleukin 2 analog is linked to one terminal of a polyethylene glycol (PEG) linker. Interleukin 2 analogs 21, 41, 52, 86, 104, and 105 were used for the preparation of the conjugate, and polyethylene glycol (ALD(2)3.4K PEG, NOF, Japan) with a molecular weight of 3.4 kDa and hydroxyl hydrogens at both terminals modified with propylaldehyde groups was used as the PEG linker, and this was linked to the N-terminus of the interleukin 2 analog. The molar ratio of the interleukin 2 analog: PEG linker was 1:15 to 1:20, and the concentration of the interleukin 2 analog was 1 mg / mL or less, and the reaction was performed at 2 to 10°C for 1 hour. The reaction was carried out in 100 mM potassium phosphate (pH 5.5), and 20 mM sodium cyanoborohydride (SCB) was added as a reducing agent. The reaction solution was changed to 20 mM triethylamine (pH 8.0) buffer using a desalting column, and then purified using a Fractogel® EMD TMAE (S) (Merck Millipore) or Source 15Q (Cytiva) column using a triethylamine (pH 8.0) and sodium chloride concentration gradient to obtain the interleukin 2 analog-3.4K PEG conjugate.

[0458]

[0459] Example 7: Preparation of interleukin 2 analog-3.4K PEG-immunoglobulin Fc region sustained conjugate

[0460]

[0461] To prepare an interleukin 2 analog-3.4K PEG-immunoglobulin Fc region sustained conjugate, the molar ratio of the interleukin 2 analog-3.4K PEG conjugate obtained using the method of Example 6 and the immunoglobulin Fc region (SEQ ID NO: 438) was adjusted to 1:10, and the total protein concentration was adjusted to 30 mg / mL, and the reaction was performed at 2 to 10°C for 15 to 16 hours. At this time, the reaction solution was 100 mM potassium phosphate (pH 6.0), and 20 mM sodium cyanoborohydride was added as a reducing agent.

[0462] The immunoglobulin region used at this time is formed by two monomers having an amino acid sequence of sequence number 438 (consisting of 221 amino acids) forming a homodimer through a disulfide bond between cysteine, the 3rd amino acid of each monomer, and the monomers of the homodimer independently form an internal disulfide bond between cysteines at positions 35 and 95 and an internal disulfide bond between cysteines at positions 141 and 199.

[0463]

[0464] Table 4 summarizes the immunoglobulin Fc amino acid sequence.

[0465]

[0466]

[0467]

[0468] After the reaction was completed, the reaction solution was purified using Bis-Tris (pH 6.5) and sodium chloride to remove unreacted immunoglobulin Fc region from Butyl FF (Cytiva), and purified using sodium citrate buffer (pH 5.5) and ammonium sulfate with Source 15ISO (Cytiva), thereby obtaining an interleukin 2 analog-3.4 kDa PEG-immunoglobulin Fc region conjugate (sustained conjugate) in which the N-terminus of the interleukin 2 analog was linked to one end of a 3.4 kDa PEG linker and the other end of the 3.4 kDa PEG linker was linked to the nitrogen of the N-terminal proline of the Fc region. This sustained conjugate was analyzed using SDS-PAGE, RP-HPLC, and SE-HPLC (Figs. 1 and 2).

[0469]

[0470] Example 8: Evaluation of interleukin 2 receptor binding affinity of interleukin 2 analog conjugates

[0471]

[0472] Surface plasma resonance (SPR, BIACORE T200, GE healthcare) was used to measure the receptor binding affinity of the interleukin 2 analog long-acting conjugate obtained in Example 7 and each of the interleukin 2 alpha and beta receptors.

[0473]

[0474] Specifically, biotin-labeled human interleukin-2 receptor alpha and beta subunits (ACROBiosystems) were immobilized on streptavidin biosensor chips (SA chip, Cytiva) at approximately 100 RU and 500 RU, respectively, and the interleukin-2 analog long-acting conjugates or aldesleukin diluted in HBS-EP+ buffer (Cytiva, BR100669) were flowed through the chips at a flow rate of 20 μL / min using a two-fold serial dilution method. After a 3-minute binding process, only HBS-EP+ buffer was flowed through the same flow rate for 3 minutes to induce dissociation of the interleukin-2 analog long-acting conjugates or aldesleukin from the interleukin-2 receptor, and the binding affinity was calculated using the association constant and dissociation constant obtained at this time. The binding affinity evaluation was performed according to the 1:1 binding fitting model in the Biaevaluation program.

[0475] The evaluated IL-2 analog conjugates were confirmed to have unique binding affinity to the IL-2 receptor, and a clear difference in binding affinity was confirmed among each candidate substance, especially at the IL-2 receptor alpha subunit. A closer look at the results showed that IL-2 analog 21 and 52 conjugates did not bind to the IL-2 receptor alpha subunit, while IL-2 analog conjugates 41, 86, 104, and 105 showed relative binding affinities of 50.8%, 65.2%, 81.0%, and 112.9%, respectively, compared to aldesleukin. In the case of the IL-2 receptor beta subunit, all IL-2 analog conjugates, including IL-2 analog 21 and 52 conjugates, showed higher binding affinity than aldesleukin.

[0476] Table 5 below summarizes the relative binding affinity (%) of interleukin-2 analog long-acting conjugates manufactured for alpha and beta receptors, based on the binding affinity of aldesleukin. In Table 5, the long-acting conjugates are indicated by the number of the interleukin-2 analog that constitutes them (e.g., the long-acting conjugate of interleukin-2 analog 21 is indicated as “interleukin-2 analog 21 conjugate”). Table 5 summarizes the binding affinity of interleukin-2 analog conjugates to interleukin-2 receptors.

[0477]

[0478]

[0479]

[0480] Example 9: Evaluation of anticancer efficacy of combined administration of interleukin 2 analog long-acting conjugate and immune checkpoint inhibitor in malignant melanoma.

[0481]

[0482] In order to confirm the anticancer effect when the interleukin 2 analog conjugate according to the present invention was administered in combination with an immune checkpoint inhibitor, the interleukin 2 analog 86 conjugate or aldesleukin (control) was administered alone or in combination with a mouse anti-PD-1 antibody (Bio X cell, Catalog# BP0146) to a syngeneic malignant melanoma mouse model (B16F10 melanoma tumor syngeneic mouse model) into which melanoma cells (B16F10) were allogeneically transplanted, and then the tumor size and individual survival rate were evaluated.

[0483] Specifically, B16F10 cells (ATCC) were injected subcutaneously into the thighs of C57BL / 6 mice, and after a few days, when tumors were observed with the naked eye, 8 mice were assigned to each group so that the tumor sizes were similar. Interleukin-2 analog 86 conjugate was administered subcutaneously once a week for a total of 4 weeks at a dose of 0.08 mg / kg or 6.0 mg / kg (based on the weight of the interleukin-2 analog part of the interleukin-2 long-acting conjugate), respectively. In addition, the control group (aldesleukin administration group) was administered 3.0 mg / kg of Proleukin Injection (Novartis) intraperitoneally once a day for 5 consecutive days, with a 2-day rest period, repeatedly administered for a total of 4 weeks. The anti-PD-1 antibody monotherapy group was administered 10.0 mg / kg of mouse anti-PD-1 antibody (Bio X cell) intraperitoneally twice a week for a total of 4 weeks. The anti-PD-1 antibody combination group was administered the same dose (10.0 mg / kg) of anti-PD-1 antibody as the anti-PD-1 monotherapy group to the interleukin-2 analog 86 conjugate 0.08 mg / kg group, 6.0 mg / kg group, and aldesleukin 3.0 mg / kg group, respectively. Tumor size 2,000 mm 3 The excess was set as the humanitarian end point.

[0484] On the 10th day of administration, the tumor size of each group (Fig. 3A) and the survival rate of each animal for 35 days (Fig. 3B) were observed. As a result, it was confirmed that the group administered 6.0 mg / kg of interleukin-2 analog 86 conjugate in monotherapy showed higher tumor suppression and individual survival rate than the control group despite administration once a week. In particular, in the group administered 6.0 mg / kg of interleukin-2 analog 86 conjugate, complete remission with complete tumor removal was observed in 2 out of 8 animals, whereas complete remission was not found in the control group.

[0485] In combination therapy with anti-PD-1 antibodies, the anti-PD-1 antibody combination group of interleukin-2 analog 86 conjugate showed higher tumor inhibition and survival rate than the anti-PD-1 antibody combination group of aldesleukin. In particular, complete remission with complete tumor removal was observed in 2 out of 8 mice in the combination group of interleukin-2 analog 86 conjugate 0.08 mg / kg and anti-PD-1 antibody, which was administered at a very low dose compared to aldesleukin. In addition, the combination group of interleukin-2 analog 86 conjugate 6.0 mg / kg and anti-PD-1 antibody showed a 100% survival rate and complete remission in 7 out of 8 mice, demonstrating superior anticancer efficacy. On the other hand, complete remission was not observed in the combination group of aldesleukin and anti-PD-1 antibody.

[0486]

[0487] Example 10: Evaluation of anticancer efficacy of combined administration of interleukin 2 analog long-acting conjugate and immune checkpoint inhibitor in Lewis lung cancer mouse model

[0488]

[0489] To evaluate the anticancer efficacy in a lung cancer mouse model, the Lewis lung carcinoma mouse model (LL / 2 tumor syngeneic mouse model) into which Lewis lung carcinoma cells (LL / 2) were allogeneically transplanted was administered interleukin-2 analog 86 conjugate or aldesleukin alone or in combination with mouse anti-PD1 antibody (Bio X cell, Catalog#BP0146), and then the antitumor efficacy was evaluated.

[0490] LL / 2 cells (ATCC) were injected subcutaneously into the thighs of C57BL / 6 mice, and after a few days, when tumors were observed with the naked eye, 10 mice were assigned to each group so that the tumors were similar in size. Each group was divided into a drug monotherapy group and a combination therapy group with an immune checkpoint inhibitor group, and the monotherapy group was assigned to an interleukin-2 analog 86 conjugate, aldesleukin, or anti-PD1 antibody group, respectively. Specifically, the interleukin-2 analog 86 conjugate administration group was administered 6.0 mg / kg of the conjugate based on IL-2 subcutaneously once a week for a total of two repeated doses, and the control group was administered 3.0 mg / kg of aldesleukin intraperitoneally once a day for 5 consecutive days, with a 2-day rest period, for a total of two repeated doses. Finally, the immune checkpoint inhibitor monotherapy group was administered anti-PD1 antibody intraperitoneally once every 3 to 4 days, twice a week for 2 weeks.

[0491] The immune checkpoint inhibitor combination group, which was established separately from the single administration group, additionally administered each interleukin-2 analog 86 conjugate and anti-PD1 antibody to the control group, and the administration concentration and interval were set to be the same as those of the single administration group.

[0492] On the 12th day of administration, the tumor size of each group was observed, and a Bliss independence model analysis was performed to evaluate drug interactions following concurrent administration with immune checkpoint inhibitors.

[0493] As a result, the interleukin 2 analog 86 conjugate not only showed excellent antitumor efficacy when administered alone in a Lewis lung cancer mouse model (Fig. 4), but also confirmed a significant synergistic effect when used in combination with an immune checkpoint inhibitor that was different from aldesleukin (Fig. 5, A and B).

[0494]

[0495] The Lewis lung cancer mouse model is a representative immune-impermeable tumor model (cold tumor), and it has been reported that the efficacy of immune checkpoint inhibitors containing anti-PD1 antibodies alone is minimal (Maryland Franklin, 2019, Labcorp). In this example, no significant anticancer efficacy was observed when an immune checkpoint inhibitor was administered alone (Figure 4). However, a synergistic effect was observed when the interleukin 2 analog 86 conjugate according to the present invention and an immune checkpoint inhibitor were co-administered. From this, it can be determined that the interleukin 2 analog conjugate of the present invention induced a transformation of the tumor microenvironment (TME) of the Lewis lung model from an immune-impermeable tumor to an invasive tumor (hot tumor), and it can be understood that this leads to an excellent effect when co-administered with an immune checkpoint inhibitor.

[0496]

[0497] Example 11: Evaluation of anticancer efficacy by combined administration of interleukin 2 analog long-acting conjugate and anti-PD-1 antibody in a pancreatic ductal adenocarcinoma (PDAC) mouse model and confirmation of memory response in a cancer cure model

[0498]

[0499] To evaluate the anticancer efficacy of interleukin-2 analog long-acting conjugates alone and in combination with anti-PD-1 antibodies against pancreatic cancer (pancreatic ductal adenocarcinoma), one of the most aggressive malignancies, allograft tumor models were generated by subcutaneously injecting mouse-derived pancreatic ductal adenocarcinoma cells (panc02) into the flanks of 6-week-old female C57BL / 6 mice. After 14 days, tumor volume (~80 mm 3 ) were randomly assigned to each group.

[0500] The trial was divided into three groups: interleukin-2 analog 86 conjugate monotherapy, anti-PD-1 antibody monotherapy, and combination therapy with both drugs. Each group was administered for a total of six weeks according to the respective dosing regimen. The antitumor efficacy of each experimental group was assessed by tumor growth inhibition (TGI) using the following formula. Table 6 shows the detailed drug dose, administration route, frequency, and antitumor efficacy for each group.

[0501] % TGI = (1-increased tumor volume from Day 0 to Day X in the experimental group / increased tumor volume from Day 0 to Day X in the negative control group) x 100

[0502]

[0503]

[0504]

[0505] *Analysis based on day 32 after drug administration, the last measurement date before tumor necrosis occurred in each group.

[0506]

[0507] Interleukin-2 analog 86 conjugate showed antitumor efficacy starting at a dose of 1.7 mg / kg and increased dose-dependently up to 25 mg / kg. No tumor suppression effect was observed compared to the negative control group in the group administered 0.3 mg / kg of interleukin-2 analog 86 conjugate and the group administered anti-PD-1 antibody alone. However, a significant level of tumor suppression effect was confirmed when the two drugs were administered together at the same dose. In particular, complete remission was observed in the group administered interleukin-2 analog 86 conjugate alone at a dose of 8.5 mg / kg or higher, and complete remission was observed in all subjects in the group administered 25 mg / kg alone or in combination with anti-PD-1 antibody.

[0508]

[0509] For subjects confirmed to have achieved complete remission, panc02 tumor cells identical to the primary tumor were injected subcutaneously into the flank on day 89 from the first dose of the drug, and the relapse prevention effect through memory response was investigated. As a result, relapse prevention efficacy through memory response was confirmed in more than 70% of the groups administered interleukin-2 analog 86 conjugate (25 mg / kg) alone or in combination with an anti-PD-1 antibody (Fig. 6). These results suggest that interleukin-2 analog 86 conjugate has the potential to not only treat primary pancreatic cancer but also prevent recurrence of the same tumor.

[0510]

[0511] The above experimental results suggest that the interleukin 2 analog long-acting conjugate according to the present invention exhibits strong anticancer efficacy and low risk of side effects through changed interleukin 2 alpha receptor and beta receptor binding affinity, and enables high blood exposure through the long-acting conjugate structure linked to the human immunoglobulin Fc region, thereby increasing the dosing interval and increasing the in vivo immune response with high activity at a low dose compared to existing interleukin 2 therapy. In addition, since it can exhibit superior anticancer efficacy through synergistic action with an immune checkpoint inhibitor, the interleukin 2 analog conjugate according to the present invention can be used for safe and effective anticancer treatment when administered in combination with an immune checkpoint inhibitor, and the interleukin 2 analog according to the present invention or the long-acting conjugate comprising the same can suppress the recurrence of cancer by inducing an immune memory response in a subject.

[0512]

[0513] From the above description, those skilled in the art will understand that the present invention can be implemented in other specific forms without altering its technical spirit or essential characteristics. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of the present invention should be interpreted as encompassing all changes or modifications derived from the meaning and scope of the following claims, and their equivalent concepts, rather than the detailed description described above.

[0514]

[0515] [Description of Nationally Supported Research and Development]

[0516] This study was supported by the National New Drug Development Project of the National Drug Development Fund (RS-2022-00165557) funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare.

Claims

1. A pharmaceutical composition for the prevention or treatment of cancer, comprising an interleukin 2 analog comprising any one sequence selected from the amino acid sequences of SEQ ID NOs: 3 to 106, characterized in that the pharmaceutical composition is administered in combination with an immune checkpoint inhibitor.

2. In the first paragraph, the interleukin 2 analog is in the form of a sustained conjugate, and the sustained conjugate is a composition represented by the following chemical formula 1: [Chemical Formula 1] X - L - F At this time, X is an interleukin 2 analog comprising any one sequence selected from the amino acid sequences of SEQ ID NOs: 3 to 106; L is a polyethylene glycol linker; F is the immunoglobulin Fc region in dimeric form; - indicates a covalent bond between X and L, and between L and F, The above-mentioned persistent complex is covalently linked to one end of L only in one polypeptide chain of the Fc region of the dimer form, and covalently linked to X in the opposite end of L.

3. A composition according to claim 1 or 2, wherein the interleukin 2 analog comprises any one sequence selected from the group consisting of amino acid sequences of SEQ ID NOs: 10, 13 to 15, 17, 20 to 22, 32, 35, 36, 42, 53, 54, 56, 58 to 60, 62, 71, 72, 74 to 78, 85, 87, 89, 91 to 94, and 97 to 106.

4. A composition according to claim 1 or 2, wherein the interleukin 2 analog comprises any one sequence selected from the group consisting of amino acid sequences of SEQ ID NOs: 17, 22, 42, 53, 56, 58 to 60, 62, 71, 72, 74 to 77, 87, 89, 91 to 93, 98 to 101, and 103 to 106.

5. A composition according to claim 1 or 2, wherein the interleukin 2 analog comprises any one sequence selected from the group consisting of amino acid sequences of SEQ ID NOs: 22, 42, 53, 87, 105, and 106.

6. A composition according to claim 1 or 2, wherein the interleukin 2 analog additionally comprises one or more amino acids at the C-terminus.

7. A composition according to claim 1 or 2, wherein the interleukin 2 analog has increased binding affinity for the interleukin 2 beta receptor compared to aldesleukin.

8. In the second paragraph, the composition wherein the immunoglobulin Fc region is derived from IgG, IgA, IgD, IgE, IgM, or a combination thereof or a hybrid thereof.

9. A composition according to claim 2, wherein the immunoglobulin Fc region is an IgG4 Fc region.

10. A composition according to claim 2, wherein the immunoglobulin Fc region is non-glycosylated.

11. In the second paragraph, the persistent conjugate is a composition in which X is covalently linked to one of the Fc regions of the dimeric immunoglobulin Fc regions via the polyethylene glycol linker.

12. A composition according to claim 2, wherein the polyethylene glycol linker is a linker having a molecular weight of 1 kDa to 100 kDa.

13. A composition according to claim 1 or 2, wherein the composition further comprises a pharmaceutically acceptable excipient.

14. In the first or second paragraph, the cancer is renal cell carcinoma, melanoma, colon cancer, liver cancer, uterine cancer, ovarian cancer, pancreatic cancer, gallbladder cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, skin cancer, breast cancer, bladder cancer, stomach cancer, head or cervical cancer, esophageal cancer, laryngeal cancer, bone cancer, rectal cancer, anal cancer, colon cancer, fallopian tube carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, small intestine cancer, endocrine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, renal pelvic carcinoma, CNS tumor, primary CNS lymphoma, spinal cord tumor, brain tumor, glioma (astrocytoma, glioblastoma), A composition comprising any one selected from the group consisting of oligodendroglioma, ependymoma, germ cell tumor, meningioma, brainstem glioma, pituitary adenoma, schwannoma, congenital tumor, craniopharyngioma, and brain tumor.

15. A composition according to claim 1 or 2, wherein the cancer is a cancer with low responsiveness to a PD-1 antagonist.

16. A composition according to claim 1 or 2, wherein the composition is administered by intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration, or rectal administration.

17. A composition according to claim 1 or 2, wherein the composition is administered at time intervals ranging from 1 week to 1 month.

18. A composition according to claim 1 or 2, characterized in that the composition is administered concurrently, separately, sequentially or in reverse order with a composition containing an immune checkpoint inhibitor.

19. A composition according to claim 1 or 2, wherein the immune checkpoint inhibitor is a PD-1 antagonist.

20. A composition according to claim 19, wherein the immune checkpoint inhibitor is at least one selected from an anti-PD-1 antibody or an antigen-binding fragment thereof.

21. A composition according to claim 20, wherein the anti-PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, cemiplimab, spartalizumab, camrelizumab, sintilimab, tislelizumab, toripalimab, dostarlimab, INCMGA00012, AMP-224, and AMP-514.